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1 Introduction 
 
Cancer is a group of diseases which is defined as the change from normal cells inside 
the body to a malignant neoplasm [1]. Malignant neoplastic cells show uncontrolled 
growth, invasion of adjacent tissues, and metastatic potential. Jointly, they lead to the 
destruction of healthy organs, and finally to the death of the organism. The change 
from a normal cell to a cancer cell is the result of genetic factors in interaction with 
external factors which are mainly the exposure of the organism to chemical, physical 
or biological carcinogens, such as asbestos, ultraviolet and ionizing radiation, or 
chronic infections from viruses and bacteria [1]. In addition, the risk for developing 
cancer increases with age and an unhealthy lifestyle [2]. 
Cancer is still one of the biggest scourges of mankind as it is the second leading cause 
of disease related deaths worldwide (around 13% of all deaths), just exceeded by 
cardiovascular diseases [2]. The International Agency for Research on Cancer reported 
12.7 million new cancer cases and 7.6 million cancer deaths in 2008 worldwide [3]. 
And the World Health Organization (WHO) expects the cancer burden to almost 
double by 2030, due to the growth and aging of world population and the increasing 
western lifestyle in developing countries [2]. The aging effect can already be observed 
in Germany, where the Robert Koch Institute reports more than 400,000 new 
incidences for 2006 (about 57% more than in the early 1980s) with a growing fraction 
of elderly and a shrinking fraction of young people [4]. However, the mortality in 
Germany decreased by more than 20% in the same time frame. This is mainly due to 
increased early detection rates and better treatment of cancers, especially of prostate 
and breast cancer, the two most common cancer types in Germany for men and 
women, respectively. 
The example of Germany shows that mortality in cancer patients can be reduced 
dramatically if cases are detected early and treated appropriately. Early detection and 
monitoring markers such as the prostate-specific-antigen (PSA) for prostate cancer or 
new treatment strategies like the monoclonal antibody trastuzumab for treatment of 
breast cancers demonstrates the usefulness of molecular markers and the importance 
of acquiring more knowledge about cancer and its molecular mechanisms.  
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Among all cancer related deaths, gastric cancer is of high clinical importance as it takes 
the third rank, worldwide [2]. The reason for this high lethality – the 5-year survival 
rate is below 30% – is that most patients are diagnosed at an advanced stage, where 
treatment options are limited [2]. Thus, new early stage detection techniques, 
treatment options and knowledge about the molecular mechanisms of gastric cancer 
are needed to improve the outcome for gastric cancer patients. 
In this context, the aim of this thesis was to investigate gastric cancer at a molecular 
level using MALDI imaging mass spectrometry. MALDI imaging mass spectrometry, 
short MALDI imaging, is a novel technology which assesses the spatial distributions of 
proteins and other molecules in tissue sections [5]. The conservation of the natural 
context of the tissue sections (morphology) combined with mass spectrometry allows 
an untargeted analysis of the molecular content of tissues resulting in cell-type 
specific molecular patterns. 
MALDI imaging has demonstrated its versatility for analyzing morphological complex 
tissues in several research areas like plant tissues [6], complex cell cultures [7], animal 
surfaces [8], or human biological systems, like the human ocular lens [9]. However, the 
application of MALDI imaging has been focused since its beginning on biomedical 
questions with the focus on cancer research. There, MALDI imaging has been applied 
in numerous clinical and preclinical studies to a variety of tumor types, amongst 
others brain, breast, lung, ovarian, prostate, and gastrointestinal cancers [10, 11].  
In this thesis, tissue sections from human gastric cancer samples were analyzed to 
discover diagnostic and prognostic protein patterns for gastric cancer which might 
enable the determination of more effective therapies. 
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1.1 Gastric cancer 
1.1.1 Epidemiology 
In 2008 gastric cancer was the fourth most common cancer-related malignancy in the 
world which led to the death of about 738,000 people taking the third rank in cancer 
related deaths (Figure 1-1) [2]. The ratio between men and women is about 2:1 [12]. 
In addition, there is a strong international imbalance with about 72% of the new cases 
happening in developing countries with highest rates in countries from East Asia and 
South America [2]. Explanations for these differences may be due to different cultural 
alimentation habits, with high consumption of salty foods and low consumption of 
fresh fruit and vegetables being associated with increased risk for stomach cancer [13, 
14]. In contrast, there has been a steady decline in stomach cancer rates in the last 
decades in developed countries such as North America and Europe [2]. Similarly, in 
Germany the incidence and mortality rate have decreased in the last 30 years, too, 
making up nowadays about 3–4% of all cancer diseases and about 5% of all cancer 
related deaths [4]. 
 
Figure 1-1 Estimated new cancer cases and deaths worldwide for the year 2008 in leading 
cancer sites. Gastric cancer was the fourth most common cancer malignancy in the world which 
led to the death of about 738,000 people taking the third rank in cancer related deaths. 
Modified from [2]. 
Despite this decline, gastric cancer is still of high clinical relevance as the five-year 
survival rate of patients in western countries remains very low with most rates below 
30%; in the US the rate is 26%, in Europe about 25%, and in Germany around 30% [2, 
4]. This is mainly due to the late detection of already advanced cancers — if the cancer 
is diagnosed at an early stage the survival rate may increase to over 60% — and the 
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lack of effective therapy options [2]. Unfortunately, less than 25% of stomach cancers 
are diagnosed at an early stage in the US and around 30% in the region of Munich and 
surroundings [15, 16]. The reason for the late detection of cancers is the absence of 
specific symptoms in the patients, the lack of sensitive serum markers and difficulties 
in detecting early stage cancers during diagnostic endoscopy; early stage cancers are 
often overlooked in a diagnostic endoscopy as they are very similar to a normal or 
inflamed stomach mucosa [17]. 
 
1.1.2 Stomach anatomy and histology 
For understanding gastric cancer it is necessary to be familiar with the anatomy and 
histology of the healthy stomach. 
The stomach is a muscular, hollow and J-shaped organ of the digestive system. It is 
located between the esophagus and the small intestine and can be divided into four 
regions: the cardia (food entry), the fundus, the body, and the pylorus (food exit) 
(Figure 1-2, A). The stomach is responsible for the mechanical and chemical disruption 
of ingested food before passing it for nutrient absorption to the intestine. The 
stomach wall is organized into four sections: the lumen-facing mucosa, the 
submucosa, the muscularis propria, and the serosa (Figure 1-2, B). The mucosa is 
separated from the underlying submucosa by a thin basal membrane. While the 
muscle layers of the muscularis propria contribute to the mixing and mechanical 
breakdown of the food, the chemical digestion is done by secretion of acids and 
proteolytic enzymes through the gastric mucosa [18]. 
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Figure 1-2 Stomach anatomy and mucosa histology. The stomach is divided into cardia, fundus, 
body, and antrum/pylorus (A). The stomach wall is structured into several layers: the epithelial 
mucosa, the submucosa, and the muscle layers muscularis and serosa (B). A magnification of 
the mucosa shows its cellular components according to which three layers can be 
distinguished: the surface epithelium, the mucosal neck, and the glandular base (C). Modified 
from [19, 20]. 
The mucosa can be divided roughly into three layers: the epithelial layer, the glandular 
neck, and the glandular base (Figure 1-2, C). The epithelial layer endues the inner 
surface of the stomach forming shallow depressions, so called gastric pits (foveolae 
gastricae). The foveolae are made up of epithelial cells which produce a carpet of 
mucus and undergo a continual replacement through division, in order to protect the 
mucosa against the aggressive contents (acids, enzymes) of the stomach. Each pit 
connects to several gastric glands that extend deep into the bottom of the mucosa. 
The layer between the gastric glands and the foveolae is called neck. The gastric gland 
is made up of different cell types [21]. The chief cells, most prominent in the base of 
the glands, secrete the proteolytic enzyme pepsin. The endocrine cells produce 
gastrins, serotonins and histamines, all of which stimulate and inhibit the production 
of the chief cells. The parietal cells are common in the neck of the glands and are 
responsible for production of hydrochloric acids which regulate the pH in the stomach. 
The regeneration of the mucosa is done by stem cells which are located at the top of 
the glandular neck. They renew the epithelial layer within 4–8 days and the glandular 
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base within 1–2 years [20]. The functional role of gastric stem cells in the pathogenesis 
of gastric tumors is not fully understood yet [21]. 
 
1.1.3 Histopathology and tumor classification  
More than 90% of malignant tumors in the stomach are adenocarcinomas, i.e. cancers 
that originate from the glands of an epithelium (see epithelial mucosa in Figure 1-2) 
[1]. Less frequent tumors of the stomach include lymphomas (4%), carcinoids (3%), 
and gastrointestinal stromal tumors (2%) [1]. Gastric adenocarcinomas are biologically 
and genetically very heterogeneous which is reflected by their broad morphological 
diversity [22]. Therefore, classification systems based on histopathological features 
have been established by which the different types of adenocarcinomas can be 
distinguished. The most common classification schemes are those of the WHO and 
Laurén [23]. 
The WHO distinguishes five categories: tubular, papillary, mucinous, signet-ring cell, 
and mixed carcinomas. While tubular and papillary tumors differ in their shapes and 
architecture of tumor cell populations, mucinous tumors are defined as being made up 
of at least 50% of extracellular mucinous pools [22]. Signet-ring cell carcinomas consist 
mostly of malignant cells containing high levels of intracytoplasmic mucin which 
pushes their nuclei against the cell membranes creating a classical signet ring cell 
appearance [23]. Mixed carcinomas display a mixture of tubular, papillary, and signet-
ring cells.  
Another widely accepted classification system is the Laurén classification [15]. 
According to Laurén, lesions are classified as intestinal, diffuse, or mixed-type tumors 
[24]. The intestinal-type gastric carcinoma is histologically moderately to well-
differentiated showing well defined glandular structures. Tumor cells are large, and 
nuclei are polymorphic and anisochromatic (Figure 1-3, A) [12]. In contrast, diffuse-
type adenocarcinomas are histologically undifferentiated. They proliferate non-
cohesively (diffuse) without gland formation (Figure 1-3, B) [25]. The diffuse-type 
resembles the mucinous and signet-ring cell tumor types of the WHO [23]. In general, 
the Laurén classification has proven useful in clinical management of patients (surgical 
therapy) and in evaluating the natural history of gastric carcinoma, especially with 
regard to its association with environmental factors, incidence trends and its 
carcinogenesis [23]. 
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Figure 1-3 Main histological gastric cancer subtypes according to Laurén. The intestinal-type 
gastric carcinoma is histologically moderately differentiated showing polypus-like expansive 
growth (A). Diffuse-type carcinoma is undifferentiated showing diffuse infiltrative growth (B). 
Mixed-type carcinomas contain tumor populations of both intestinal and diffuse-type. 
Carcinomas of the above mentioned categories which are confined to the mucosa or 
submucosa are called early stage gastric cancers. 
 
1.1.4 Etiology and carcinogenesis 
The main two tumor types according to Laurén (diffuse and intestinal) differ in both 
their etiology as well as their carcinogenesis [26]. 
The development of intestinal-type gastric cancer has been associated with certain 
dietary factors like high intake of salty and smoke-preserved foods, and low intake of 
fruit and vegetables [15, 22]. Additional risk factors include smoking and a previous 
partial gastrectomy [15]. 
Major risk factor, however, is the infection with the bacterium Helicobacter pylori (H. 
pylori) which may provoke a chronic gastritis in the stomach [1]. The gastritis develops 
as a result of the combined influence of enzymes and toxins secreted by the bacterium 
and the release of noxious chemicals by the recruited neutrophils [1]. In this context, 
cancer risk increases with inflammatory intensity which depends on the 
aggressiveness of the H. pylori strain and on genetic factors in the host, e.g. 
polymorphisms in cytokine genes which may increase sensitivity to inflammation [25]. 
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It has been proposed that the intestinal-type cancer develops, after initial chronic 
gastritis, through a sequence (Correa sequence) of precursor lesions (atrophic 
gastritis, intestinal metaplasia, and dysplasia) toward cancer (Figure 1-4) [12]. 
Histologically, chronic gastritis is characterized by a diffuse infiltration of the gastric 
mucosa by white blood cells with a good preservation of mucosal glands [27]. Loss of 
glands (atrophy) and their replacement by fibrous tissue is the next step toward 
neoplasia, and is called atrophic gastritis [27]. Next, at the stage of intestinal 
metaplasia, glands and the foveolar epithelium are replaced by metaplastic cells that 
resemble the morphology of the small intestinal or colonic mucosa [27]. Importantly, 
up to this point cells show normal cytological appearance [27]. Subsequent dysplasia 
features atypical changes in nuclear morphology and tissue architecture. Usually, cells 
of the dysplastic epithelium are enlarged, hyperchromatic, irregular in shape, and 
devoid of polarity [27]. The tissue architecture shows irregular structures, frequently 
forming adenomas with irregular lumens [27]. If a dysplasia breaks through the basal 
membrane into the submucosa, it is considered a carcinoma [22]. 
 
Figure 1-4 Correa sequence of precursor gastric cancer lesions. The sequence shows the 
proposed development of intestinal-type gastric cancer through a series of sequential 
precursor lesions which are histologically depicted from left to right: normal mucosa, chronic 
gastritis, mucosal atrophy, intestinal metaplasia, dysplasia, and finally intestinal-type 
carcinoma. Modified from [12]. 
In contrast, the carcinogenic pathway for diffuse-type gastric cancer is believed to 
develop through a shorter, still unidentified sequence of events from gastric epithelial 
cells [25]. 
Crucial for the development and progression of cancer is the accumulation of genetic 
defects. Genetic changes that happen during cancer development have been reported 
(Figure 1-5) [25]. Chronic infection might trigger the expression of important proteins 
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such as CDX2. This is a transcription factor that is important for the early 
differentiation and maintenance of intestinal epithelial cells which was found to be 
associated with the formation of intestinal metaplasia [28]. Further alterations for 
development of intestinal-type gastric cancer include loss or mutations in APC [29] 
and KRAS [30], and hypermethylation of promoter regions of mismatch repair proteins 
such as MLH1 [31]. Loss of TP53 could be found in both Laurén types [25]. Dysfunction 
of E-cadherin, an epithelial cell adhesion protein, is present in 50% of diffuse-type 
carcinomas [32]. Inherited mutations in the E-cadherin gene CDH1 are responsible for 
1–3% of gastric cancers, called hereditary diffuse-type gastric cancer [12]. 
 
Figure 1-5 Models of the gastric carcinogenic pathway. Different sequences of events for 
developing intestinal or diffuse type gastric carcinoma have been proposed by Yuasa [25]. 
While defects in E-cadherin function are specifically associated with diffuse-type gastric cancer, 
non-hereditary carcinomas usually involve Helicobacter pylori infection. Subsequent 
inflammatory response and regeneration processes, together with genetic aberrations, may 
finally induce the carcinogenic sequence. Taken from [25]. 
Other molecular or genetic events drive the further behavior of the tumor. For 
instance, amplification of the HER2 gene which is frequent in about 7–34% of gastric 
cancers was found to be correlated with a poorer prognosis and liver metastases [33, 
34]. On the contrary, loss or mutation of the PTEN gene was found in 20–30% of 
patients associated with metastatic gastric cancer [31]. 
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1.1.5 Diagnosis and staging 
Symptoms and diagnosis 
In early stage gastric cancer symptoms are vague and therefore unrecognizable by the 
patient for several months or years [15]. Symptoms of advanced gastric cancer show 
pain in the abdominal region, stool bleeding, dysphagia, and vomiting. Systemic 
symptoms like aversion to meat and weight loss indicate disseminated disease. Thus, 
80–90% of patients with symptoms presenting themselves to the physician have 
advanced cancer [23]. In some cases, the physician can detect the palpable advanced 
cancer (transmural tumor extension or enlarged lymph nodes) by body examination 
[15]. Serum based tumor markers like CEA, CA125, CA19-9, and CA72-4 have shown 
not to be reliable for diagnosis or staging [15]. Endoscopy of the upper gastrointestinal 
tract in combination with histological evaluation of biopsies is regarded the most 
sensitive and specific diagnostic method for detection of the tumor [23]. 
Staging 
After detection, correct staging of the tumor is the most important requisite for an 
optimal therapy of the patient. The most widely used staging system for most tumor 
entities is the tumor-node-metastasis (TNM) classification system that is maintained 
by the Union for International Cancer Control (UICC), which is in its seventh edition 
[35]. The T category describes the extent of the primary tumor, N the status of 
regional lymph node metastasis, and M the absence or presence of distant metastasis. 
The degree of disease extent for each class is indicated by a tailing number, where a 
higher number correlates with an advanced disease stage. For practical purposes, 
TNM combinations can be condensed into stage groups which differ in their prognosis 
and appropriate treatment. In the TNM system, classification rules have been 
established for carcinomas of the stomach (Table 1-1). 
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Table 1-1 TNM classification system for gastric cancer 
TNM categories Stage T N M 
Extension of the primary tumor (T) 
 
IA T1 N0 M0 
 
Tis Carcinoma in situ: intraepithelial tumor, high grade dysplasia 
 
IB T1 N1 M0 
 
T1a Tumor invades lamina propria or muscularis mucosae 
  
T2 N0 M0 
 
T1b Tumor invades submucosa 
 
IIA T1 N2 M0 
 
T2 Tumor invades muscularis propria 
  
T2 N1 M0 
 
T3 Tumor invades subserosa 
  
T3 N0 M0 
 
T4a Tumor perforates serosa 
 
IIB T1 N3 M0 
 
T4b Tumor invades adjacent structures 
  
T2 N2 M0 
Metastasis of regional lymph nodes (N) 
  
T3 N1 M0 
 
NO No regional lymph node metastasis 
  
T4a N0 M0 
 
NX Less than 16 investigated lymph nodes 
 
IIIA T2 N3 M0 
 
N1 1–2 regional lymph nodes affected 
  
T3 N2 M0 
 
N2 3–6 regional lymph nodes affected 
  
T4a N1 M0 
 
N3a 7–15 regional lymph nodes affected 
 
IIIB T3 N3 M0 
 
N3b 16 or more regional lymph nodes affected 
  
T4a N2 M0 
Distant metastases (M) 
  
T4b N0/N1 M0 
 
M0 No distant metastasis 
 
IIIC T4a N3 M0 
 
M1 Distant metastasis present 
  
T4a N2/N3 M0 
    
IV any any M1 
 
For practical assessment of TNM categories before surgery, different methods are 
employed. The depth of infiltration of the tumor (T category) can be best evaluated by 
endoscopic ultrasound [15]. This procedure may be also employed to determine near 
lymph node involvement (N category) [15]. More distant affected lymph nodes may be 
detected by X-ray computed tomography (CT) [12]. CT and other imaging modalities 
like abdominal sonography or positron emission tomography (PET) can be used to 
identify distant metastasis in the body (M category) [15]. 
Other histopathological categories have been introduced which require a tissue 
sample either from a surgery or bioptic analysis. A staging based on a pathological 
classification of a tissue sample is considered the most reliable classification and is 
indicated by a leading ‘p’ in the TNM nomenclature, e.g. pT1N1. 
The grading category (G) classifies the carcinomas according to their grade of 
differentiation into the classes G1 to G4, where a higher number indicates a less 
differentiated tissue with regard to the healthy glandular structure. The differentiation 
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of a tumor is also reflected in the Laurén system, where diffuse type tumors represent 
poor differentiated carcinomas.  
The absence or presence of residual tumor after surgery is described by the symbol R. 
R0 indicates full resection of tumor, R1 and R2 microscopic and macroscopic residual 
tumor, respectively [35]. Resection status strongly influences prognosis and thus 
further procedures after initial treatment [12, 36]. 
The TNM staging and its supplemental categories are the most important factors for 
an adaptation of the therapy to the individual situation of the patient. However, 
prognosis varies widely among patients of the same stage [37]. Thus, the complete 
applied therapy has to consider also other parameters such as the histopathological 
classification of the tumor, like Laurén subtypes, or molecular factors such as HER2 
expression status, in order to apply optimal treatment for each patient. 
 
1.1.6 Therapy 
Surgery 
Surgical therapy is the main pillar of gastric cancer treatment. The aim of this therapy 
is always the complete removal of primary tumor and affected lymph nodes, as 
incomplete resections, i.e. residual tumor at the resection margins (R1 or R2), worsen 
prognosis for the patients dramatically [15]. The appropriate surgical treatment 
depends on the previously determined tumor stage. Early stage gastric cancers (stage 
Ia) are mainly removed by endoscopic or laparoscopic surgery dependent on tumor 
differentiation and size [12]. In locally advanced cancers (stages Ib–IIIa) the chance of 
lymph node metastasis is already high. Thus, besides full resection (R0) of the tumor 
by full or partial gastrectomy, extended lymph node excision is recommended [15]. As 
mentioned before, the degree of resection is also determined by the histological type 
of tumor; a diffuse type cancer needs a more radical resection than intestinal type 
[15]. Patients suffering from advanced cancers (stages IIIb–IV) have infiltration of 
neighbor organs and/or distant metastasis which may not be surgically removed. In 
these cases, radio-chemotherapeutic approaches or treatment with biological agents 
like antibodies become important. 
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Neoadjuvant and adjuvant therapy 
It seems likely that surgical therapy for local tumor control  can – at least in developed 
countries – only be marginally improved [12]. Therefore, the effect of additional 
treatments by different cytostatic drugs (chemotherapy) in combination with 
radiotherapy is under strong investigation. Preoperative therapy actions are called 
‘neoadjuvant’, and postoperative actions ‘adjuvant’. It has to be mentioned at this 
point that existing guidelines for treatment of gastric cancer differ. In consequence, 
the following description will embrace, and not differentially explain, current 
treatment strategies for gastric cancer. 
The rationale behind neoadjuvant therapies is three-fold: (i) it increases the 
probability for the application of the appropriate therapy (compliance) [15], (ii) the 
treatment is expected to downsize the tumor, thus facilitating a full surgical resection 
(R0) [12, 15], and (iii) this systemic preoperative therapy is the earliest way to delay 
systemic tumor spread [15]. The effect of neoadjuvant chemotherapy has been 
investigated in several studies which reported a beneficial effect for patients 
undergoing multimodal therapy [38, 39]. Consequently, this treatment option has 
been implemented in several national gastric cancer treatment guidelines [15, 36]. 
Initial studies on preoperative exposure of patients to radiation only or in combination 
with chemotherapy have shown promising results which have to be confirmed in 
larger patient cohorts [15].  
Adjuvant approaches also include chemo- or radiotherapy. Present consent in 
guidelines is the application of combined chemoradiotherapy in a postoperative 
setting for locally advanced tumors and/or incomplete tumor resection [12, 36, 40]. 
Chemotherapy only is mostly considered when tumor is at an unresectable stage [37]. 
However, not all patients respond to chemotherapeutic pre- or postoperative 
treatment [15]. Thus, it would be useful to predict which patient will benefit from such 
a treatment and which not, as identified non-responders would not suffer from 
delayed surgical actions and chemotherapeutic side effects. One way that is believed 
to address this problem is the employment of molecular biomarkers [41]. One part of 
the thesis is dealing with the determination of such molecular markers, which is 
described in the results chapter 2.4. 
Novel approaches 
Despite all the above mentioned treatment options and strategies, the five-year 
survival rate of patients in western countries remains mostly below 30% [2]. Thus, 
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novel therapeutic agents, mostly in combination with established chemotherapeutic 
regimens, are being investigated in several clinical trials for advanced gastric cancers. 
Amongst them are also biological agents like the anti-EGFR antibody panitumumab 
(ClinicalTrials.gov Identifier: NCT00824785) or the EGFR inhibitor cetuximab 
(ClinicalTrials.gov Identifier: NCT00678535). Others include the tyrosine kinase 
inhibitor lapatinib (ClinicalTrials.gov Identifier: NCT00486954), the multi-targeted 
receptor tyrosine kinase inhibitor sunitinib [42], and the therapy with histone 
deacetylase inhibitors such as vorinostat (ClinicalTrials.gov Identifier: NCT01045538). 
HER2 targeted therapy 
The fact that patients can benefit from an additional treatment by biological agents, 
like antibodies, has been proven recently by the results of the ToGA Phase III trial [33]. 
This study investigated the effect of safety and efficacy of trastuzumab (trade name 
‘Herceptin’, Hoffman-La Roche, Basel, Switzerland) in combination with regular 
chemotherapy in patients with HER2-positive, advanced gastric cancer [33]. Previous 
studies have identified HER2 overexpression to be associated with a poor outcome of 
patients with gastric cancer [43, 44]. HER2 overexpression is found in about 20% of 
gastric cancer patients with a significant bias toward intestinal type [37, 45]. 
Trastuzumab is a monoclonal antibody specifically targeting HER2 (also known as 
ERBB2), a human epidermal growth factor receptor. The therapeutic effect by 
trastuzumab is not fully understood yet, but it is believed to inhibit proliferation by 
blocking signaling pathways (Figure 1-6) [37]. 
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Figure 1-6 Protein signaling pathway involved in trastuzumab response. Trastuzumab (trade 
name ‘Herceptin’) is an antibody that recognizes HER2 and inhibits proliferation by blocking the 
down-stream signaling pathways. Taken from [46]. 
The ToGA trial provided evidence of a significant higher median survival for patients 
assigned to the trastuzumab treated arm (13.8 vs. 11.1 months; hazard ratio 0.74; 95% 
confidence interval: 0.60-0.91; p<0.0046) (Figure 1-7) [33]. 
16 
 
 
Figure 1-7 Overall survival benefit of trastuzumab treated patients with HER2-positive 
advanced gastric or gastro-esophageal junction cancer. Median overall survival (13.8 months) 
in those assigned to trastuzumab plus chemotherapy was significantly higher (hazard ratio 
0.74; p=0.0046) than compared with those assigned to chemotherapy alone (11.1 months). 
Taken from [33]. 
In breast cancer, treatment with antibodies has been established as a standard option 
for HER2-positive patients. Likewise, new guidelines for gastric cancer treatment now 
recommend routine evaluation of HER2 status in gastric cancer specimens [36, 47]. 
HER2 testing 
It is important that trastuzumab can only be used when the cancer has been shown to 
overexpress HER2. Currently, two testing methods are approved by the U.S. Food and 
Drug Administration for HER2 expression testing in cancer tissues in a clinical setting: 
immunohistochemical analysis (IHC) and fluorescence in situ hybridization (FISH). A 
modified breast cancer HER2 scoring system has been proposed for gastric cancer 
[48]. The differences are due to a different membrane staining pattern, a more 
frequent heterogeneity of HER2 positivity in gastric cancer and a less stringent 
correlation between HER2 amplification and protein overexpression [49]. According to 
this scoring system, a patient was only considered HER2-positive with a score of IHC3+ 
and/or a FISH-positive result, which is defined as HER2/centromer 17 ratio >2.2 or an 
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average HER2 gene copy number greater than six [48].However, both HER2 testing 
procedures, IHC and FISH, suffer from several disadvantages [50-52].  
A mass spectrometry based approach may complement the two standard techniques 
because it offers multiplexing capability, i.e. the simultaneous measurement of several 
parameters at the same time. This is especially interesting in breast cancer where 
HER2, estrogen and progesterone receptor status are currently determined 
sequentially. Proof of an accurate HER2-status determination was provided by a study 
on basis of proteomic expression profiles obtained by MALDI imaging mass 
spectrometry [53]. In this work, the combination of seven mass signals was able to 
accurately define HER2-positive from HER2-negative breast cancer tissues, highlighting 
the potential of other analytical methods for tissue diagnostics (Figure 1-8) [53].  
The example of HER2 shows that molecular prognostic factors can also act as novel 
therapeutic targets for either chemotherapeutics or biological agents like antibodies 
[37]. Thus, the aim should be to identify novel molecular markers with clinical 
relevance. 
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Figure 1-8 HER2 status correlated protein pattern in breast cancer. MALDI imaging was used to 
analyze 30 HER2 predefined breast cancer specimens which led to the discovery of a 7-signal 
protein pattern (top) which strongly correlated with the HER2 status of patients, as the 
hierarchical clustering on the 30 patients showed only two false positives (bottom, 93% 
accuracy). Taken from [53]. 
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1.2 Proteomics for biomarker discovery 
1.2.1 Biomarkers 
The morphology based TNM staging system remains useful, but there is a variety in 
outcomes for patients with cancers of the same type or stage [54]. New factors like 
individual molecular markers or patterns may therefore subdivide traditional tumor 
classes into subsets that behave differently from each other [54]. Such biomarkers 
may aid in risk assessment, diagnosis of cancer, or monitor recurrence [55]. With 
regard to therapy they may act as prognostic indicator of disease progression or 
predict therapy response; thus, help establishing a personalized therapy for each 
patient. The different applications of biomarkers in stages of clinical evolution of 
cancer are depicted in Figure 1-9 [54]. In addition, these markers and their respective 
pathways may be starting points for further investigations which may lead to new 
therapeutic agents. 
 
Figure 1-9 Use of biomarkers in stages of clinical evolution of cancer (A). Before diagnosis, 
markers might be used for risk assessment and screening. At diagnosis, markers can assist with 
staging, grading, and selection of initial therapy. Later, they can be used to monitor therapy, 
select additional therapy, or monitor for recurrent disease. As example, used clinical methods 
and biomarkers for breast cancer are listed in (B). Taken from [54]. 
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Grouping of biomarkers 
Regarding clinical application, most biomarkers fall into one of the following 
categories: 
 Diagnostic markers: are used to detect cancer in a person and may thus also 
be used as monitoring marker after therapy or as screening marker 
 Prognostic markers: are used to predict the course of disease and thus 
influence the aggressiveness of therapy 
 Predictive markers: are used to predict whether a patient will respond to an 
applied therapy (mostly chemotherapy or targeted therapy) 
In addition, biomarkers can be grouped also according to their biochemical molecule 
class. To account for the molecular complexity of tumors, markers have been searched 
on all molecular levels including: 
 DNA-based markers: single nucleotide polymorphisms (SNPs), chromosomal 
aberrations, DNA copy numbers, microsatellite instability, and differential 
promoter-region methylation  
 RNA-based markers: differential expression of mRNAs or regulatory RNAs 
like microRNAs 
 Protein-based markers: differential expression of proteins or their post-
translational modifications, such as proteolytic processing, acetylation, 
phosphorylation, or glycosylation, all of which are important processes in 
determining protein function 
 Other molecular classes such as lipids, saccharides, or hormones 
 Signatures: represent patterns of the above listed molecular entities (mostly 
RNA or protein expression profiles) 
Requirements for biomarkers 
The ideal features of a tumor marker or signature depend on the clinical question. 
However, in general an ideal biomarker should meet the following requirements: (i) 
high sensitivity and specificity for determination of clinical conclusion e.g. diagnosis; 
(ii) a cheap, rapid, and reproducible measurement; (iii) easy (best: non-invasive) access 
to the site of marker assessment such as plasma, serum or other body fluids [56]. 
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It is a general agreement that combinations of multiple biomarkers may increase 
sensitivity and specificity, especially if positive and negative biomarkers are included 
into the signature [56]. In addition, a combination of these molecular species may not 
only increase general accuracy, but would remain more robust at a statistically 
significant level, as it has been reported that individual markers may vary for a variety 
of reasons [57]. Signatures are mostly combined to a classifier by statistical methods 
like decision trees, support vector machines, or clustering algorithms (for details see 
chapter 4.2.2 in statistical methods). 
The proteome as biomarker source 
In my studies presented here, I focused on the analysis of proteins as markers. The 
rationale is that proteins execute and control the vast majority of biological processes 
and thus reflect both the intrinsic genetic information of the cell as well as the 
influence of its environment [58]. The variety of proteins expressed in humans 
surpasses the number of protein-encoding genes by an order of magnitude (not 
considering their modifications) [58]. Furthermore, it has been realized that studying 
biological systems solely by mRNA expression is not sufficient as there is no absolute 
correlation between mRNA and corresponding protein levels [59]. In consequence, 
one of the best ways complex biological system are reflected is by proteins where the 
differences between various states of a biological system are reflected in the different 
amounts, activities, localizations and interactions of proteins [60]. All proteins present, 
including their modifications, in an organism or biological system at a certain state 
(disease, stress, normal circumstances), is called ‘proteome’. 
 
1.2.2 Sources of protein biomarkers 
In an organism, protein markers can be produced either by the tumor itself or by other 
cells in response to the presence of the cancer, like inflammatory cells [41]. The 
markers are, therefore, expected to be present at highest concentration at the site of 
tumor or near reactive tissue, but may be also found in smaller concentrations in 
biological fluids, human excrements or secretions like plasma, serum, urine, stool, 
saliva, pancreatic juice etc. However, the most common sources used for biomarker 
discovery are blood and tumor tissues [55]. Other used sources for biomarker 
discovery may be cancer cell lines or animal models which are discussed more in detail 
by Kulasingam et al. [55]. 
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Blood derived fluids 
The main advantage of using blood derived fluids is that it can be obtained easily 
through a minimal invasive procedure, it is abundantly available, and that some blood 
components reflect several pathological states [55]. However, the protein 
concentrations in plasma differ in more than ten orders of magnitude (22 proteins 
make up 99% of the plasma proteome), making untargeted protein analyses very 
difficult [55, 61]. In addition, untargeted protein analyses on fluids have shown in the 
past that the proteins which were detected were often not tumor specific or even not 
reproducible, which may be due to active proteases, lipids, and other compounds 
which may depend on sample preparation variations [55, 56, 62, 63]. 
Tissues 
Tumor tissues are more difficult to obtain as they must be removed invasively during 
surgery or during biopsy removal. However, they are considered a promising source 
for marker discovery. The rationale is that tissue samples contain higher 
concentrations of candidate proteins originating from tumor tissue that could 
subsequently be measured by targeted, and thus more sensitive, approaches in the 
bloodstream [55, 64]. Of importance, one has to consider that tissue may be 
extremely heterogeneous both in its cellular and molecular composition. Thus, a 
differentiated analysis of tissues can only be performed by technologies that take this 
complexity into account. 
 
1.2.3 Proteomics for tissue analysis 
In general, methods for the analysis of tissues can be divided into two groups: on the 
one hand lysate-based methods where structural information of the tissue is lost and 
on the other hand in situ methods that conserve the morphology, i.e. the tissue 
structure. 
Classical in situ methods for studying proteins like the immunohistochemistry enable 
to study the spatial distribution of molecules within in tissue sections. However, they 
are not suitable for screening of biomarkers, as they require the labeling of the target 
molecules in advance by specifically binding dyes or antibodies in combination with 
chromophores or fluorophores [65]. In addition, only a few features can be labeled at 
the same time. 
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In contrast, lysate-based methods can analyze the molecular content of tissue without 
previous knowledge in a multiplex approach and are therefore technically very 
suitable for screening purposes, i.e. for de novo biomarker discovery. However, the 
unlabeled analysis of the proteome puts high demands on the analytical techniques as 
the human proteome is very complex. It is predicted to contain up to 1 million 
proteins resulting from the over 300 known post-translational modifications that can 
occur in different combinations with the different splice variants during expression 
[66]. In addition the proteins have a wide dynamic range in abundances (10
10
, as 
shown for the plasma proteome) [61]. 
The technology for the large-scale study of the proteome is called ‘proteomics’ in 
analogy with large-scale genomics or transcriptomics initiatives. In proteomics, several 
lysate-based techniques have been established for the large-scale study of proteins 
with regard to their expression, structure, and function (Figure 1-10) [60]. 
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Figure 1-10 Technologies for proteomics. The figure shows the proteomic workflow from 
sample extraction to protein quantification. For each step in the workflow, a variety of 
techniques exist that are used for the large-scale study of proteins, termed proteomics. Taken 
from [60]. 
Especially mass spectrometry has become a key technology in proteomics as it offers 
an unlabeled high-throughput analysis of the molecular content of samples, ranging 
from small molecules over macromolecules, such as proteins, to modifications of 
proteins. Other techniques, such as the two-dimensional gel electrophoresis and the 
protein microarrays, fail to achieve the depth of informative proteome analysis as 
seen with mass spectrometry [67].  
Nevertheless, in lysate-based analyses of tissues the localization of the analytes 
remains unknown. This makes interpretation of the results difficult, as the results may 
be blurred by the morphological complexity of the tissue. 
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In order to reduce this morphological complexity while maintaining cellular specificity 
of molecular analysis, laser capture microdissection (LCM) can be performed to isolate 
cells and tissue components of interest prior to analysis [64]. However, LCM is a highly 
tedious process while yielding low number of cells [55]. Consequently, the final 
amount of material puts even more sensitivity demands on analytical approaches [63]. 
One novel technology that overcomes this process is imaging mass spectrometry. 
Imaging mass spectrometry is an in situ technique with the advantages of lysate-based 
approaches. It offers mass spectrometry based analyses of the molecular content of 
tissue sections while preserving their morphological integrity. One of the most 
commonly employed imaging mass spectrometry techniques is MALDI imaging mass 
spectrometry, as it allows to measure large and small molecules at a reasonable 
spatial resolution with a simple technological set-up (in comparison to other imaging 
mass spectrometry technologies). 
 
1.2.4 MALDI imaging mass spectrometry for tissue analysis 
MALDI imaging is a mass spectrometry based approach which allows investigating the 
spatial distribution of proteins, lipids, drugs and other molecules in their 
morphological context of tissue sections (Figure 1-11). Conversely, it allows allocating 
molecular profiles to histomorphological entities, such as tumor areas etc. For this, 
MALDI mass spectra are acquired as pixels across a tissue section. A more detailed 
technological description of its principle, its workflow, advantages and limitations, can 
be found in the technical appendix of this thesis (chapter 4.1). 
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Figure 1-11 Technical principle of MALDI imaging mass spectrometry. A tissue section is coated 
with matrix before multiple MALDI experiments are performed in a predefined raster across 
the tissue section. After measurement, the intact section can be stained and digitally scanned 
for co-registration to the spatially resolved mass spectrometric data. This allows visualizing the 
distribution of masses within their morphological context of the analyzed tissue section. 
Abbreviations used: m/z, mass-to-charge-ration; MALDI, matrix-assisted laser 
desorption/ionization. Taken from [68]. 
Initially, two important studies gave evidence for the usefulness of direct MALDI tissue 
analysis to obtain meaningful protein signatures with clinical relevance from disease 
tissues. The first study, published in The Lancet, was able to distinguish different lung 
cancer histological entities, regional and distant metastasis, and finally survival of non-
small-cell lung cancer patients by protein signatures [69]. Similarly, Schwartz and 
coworkers identified protein patterns that correlated with tumor histology and patient 
survival using a data set of 108 glioma patients [70]. Subsequently, MALDI imaging has 
been applied in numerous clinical and preclinical studies to a variety of tumor types, 
amongst others brain, breast, lung, ovarian, prostate, and gastrointestinal cancers 
[10]. These studies investigated tumor protein profiles obtained from tissues by 
MALDI imaging for correlation with clinical endpoints, like disease stage, survival, 
tumor recurrence, or therapy response [11, 71-74]. 
The spatially resolved data obtained by MALDI imaging also facilitates to investigate 
intra-sample molecular details such as tumor-normal interface zones or tumor 
heterogeneity in combination with the histomorphological information [75, 76]. 
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With regard to the topic of this thesis, a summary of proteomic studies in diseases of 
the human lower and upper gastrointestinal system is presented in Table 1-2. 
Although the studies conducted are so far low in sample number, they illustrate the 
potential of histology-based analyses by MALDI imaging to provide novel biomarkers 
or patterns for a variety of different clinical purposes. 
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Table 1-2 Proteomics studies in gastrointestinal diseases using MALDI imaging mass 
spectrometry. Taken from [77] 
Disease Publication Protein Mass [Da] Clinical purpose Validation 
Barrett's 
cancer 
Elsner et al. [78] 61-protein signature - Carcinogenesis - 
 COX7A2 6720 Carcinogenesis 
/Prognosis 
IHC 
 S100-A10 11185 " IHC 
 28-protein signature - Marker for regional 
lymph node metastasis 
- 
 TAGLN2 22262 Marker for regional 
lymph node 
metastasis/Prognosis 
IHC 
Stomach 
cancer 
Kim et al. [79] 73-protein signature - Tumor detection - 
 DEFA1 3439 " - 
 DEFA2 3368 " - 
 S100-A8 10840 " - 
 S100-A9 13158/12694 " - 
 17-protein signature - Early vs. advanced 
stage 
- 
Balluff et al. [80] 7-protein signature - Prognosis in intestinal 
type gastric cancer 
- 
 DEFA1 3445 " IHC 
 CRIP1 8406 " IHC 
 S100-A6 10098 " IHC 
Liver cancer Le Faouder et al. [81] 13-protein signature - Tumor marker - 
 Ubiquitin 8565 " IHC, PCR 
Liver 
autoimmune 
diseases 
Bowlus et al. [82] 10-protein signature - Distinction of 
autoimmune hepatitis 
and primary sclerosing 
cholangitis 
- 
Pancreatic 
cancer 
Djidja et al. [83] Grp78 72288 Tumor marker IHC 
Colon 
colitides 
M'Koma et al. [84] 5-protein signature - Distinction of ulcerative 
colitis and Crohn's 
colitis 
- 
Colon 
cancer 
Meding et al. [85] 50-118 protein signature - Classification of cancer 
of unknown primary 
(liver metastasis from 
primary colon cancer) 
- 
Meding et al. [86] FXYD3 9264 Marker for regional 
lymph node metastasis 
IHC 
  S100-A11 11646 " IHC 
 
Some of the studies performed in gastric cancer will be explained more in detail in the 
following subsection. 
Applications in gastric cancer 
The potential of MALDI imaging for diagnostic purposes to detect gastric cancer has 
been investigated on endoscopic biopsies. Kim et al. used histology-directed MALDI 
profiling to analyze 63 gastric cancer and 43 healthy endoscopic biopsies. They found a 
protein profile which classified samples cancerous or healthy samples in the validation 
set with high predictive values: sensitivity and specificity were 93.8% and 95.5%, 
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respectively [79]. Signals overexpressed in tumors were identified as α-defensin-1, α-
defensin-2, calgranulin A, and calgranulin B. Furthermore, a second protein profile 
could distinguish pathologic AJCC (American Joint Committee on Cancer) stage Ia from 
more advanced stage patients (Ib or higher). This may be potentially useful in 
identifying as patients with stage Ia that may be eligible for endoscopic treatments 
instead of surgical therapy [36]. 
This study shows that useful molecular profiles can be obtained by MALDI analyses 
from even smallest amounts of unprocessed fresh frozen tissue samples like biopsies 
for assisting in the diagnosis of cancers. 
Human gastric cancer tissues are known to be very heterogeneous [87]. This may be 
due to the intrinsic heterogeneity of solid tumors based on e.g. distinct grades of 
differentiation, local differences in metabolic activity, the local inflammatory 
response. [88]. 
MALDI imaging may allow assessing this complexity. This has been shown in a first 
study by Deininger et al. on ten sections of gastric cancer patients which were 
subjected to MALDI imaging analyses. The in situ proteome expression profiles were 
analyzed by hierarchical clustering and were found in good correlation with the 
histological structure of the samples (Figure 1-12). But more interestingly, this 
examination revealed also histologically invisible distinct tumor areas. This shows that 
MALDI imaging may detect phenotypic differences in tissues, such as tumor subclones, 
that are invisible by conventional morphology based methods [88]. 
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Figure 1-12 MALDI imaging for the detection of tumor heterogeneities beyond histology. The 
application of a hierarchical clustering to single spectra of a stomach tumor sample measured 
by MALDI imaging is shown. In (D) the top three branches of the clustering show the solid 
tumor in blue, as visualized in (C); pixels are colored according to the color of the dendrogram 
nodes. Expansion of the tumor branches of the clustering tree lead to a more detailed 
clustering of the spectra in the solid tumor (F), revealing phenotypic differences beyond 
histology (E), for example, tumor subclones. Taken from [88]. 
The applicability of MALDI imaging to FFPE tissue microarrays, which might enable 
high-throughput analyses, has been shown in a very small study (n=12). Formalin-fixed 
paraffin-embedded tissue microarrays comprising nine gastric cancer and three 
normal stomach tissue cores have been analyzed by Morita et al. After tryptic digest, 
they found 14 signals to distinguish gastric cancer samples of different differentiation 
grades and 54 signals to separate healthy from cancer tissues [89]. Tandem mass 
spectrometry identified one of the signals as histone H4, which was remarkably 
strongly expressed in poorly differentiated cancer tissues [89]. 
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1.3 Aims of thesis 
The overall aim of my thesis was to discover novel biomarkers in different 
gastrointestinal cancers (colon, gastric, and Barrett’s cancer) with the focus on gastric 
cancer. 
Biomarkers might enrich the possibilities to aid in early detection, prediction of 
therapy response, prognosis or potential to metastasize in patients with cancer. 
Molecular biomarkers can be searched on a genetic, transcriptomic, proteomic, or 
epigenetic level (DNA methylation, histone modifications) in tissues or body fluids. 
With the intention to search for biomarkers on a protein and epigenetic level in tissue 
samples of patients, I set up own studies in gastric cancer and participated in studies 
of colon and Barrett’s cancer. 
In gastric cancer, matrix-assisted laser desorption/ionization (MALDI) imaging mass 
spectrometry (“MALDI imaging”) was used for the morphologically differentiated 
analysis of tissues in order to acquire cell type specific (such as from tumor cell 
populations, inflammatory cells, etc.) protein expression patterns that can be 
correlated with clinical endpoints of the patients. 
A major challenge faced by clinicians treating patients with gastric cancer is how to 
best assess patient outcome and predict the clinical course of the disease in order to 
apply the most appropriate treatment regimen. Thus, in one study, the tumor protein 
profiles obtained by MALDI imaging were used to discover novel protein biomarkers in 
human gastric cancer tissues that indicate the overall survival of patients. In another 
study, tumor protein profiles were used for generating a classifier that determines 
HER2 status in gastric cancer patients. The HER2 expression status is important for 
therapy selection with regard to the administration of Herceptin. This study was based 
on our previous results where HER2-status could be reliably predicted in breast cancer 
patients [53]. 
Importantly, the selection of samples from a tissue collection is crucial for the success 
of a research study. In both studies this selection has been performed carefully. This 
includes histological evaluation and matching for clinical parameters (as good as 
possible) except the one that is investigated, while maintaining the number of samples 
in the study cohort high in order to guarantee sufficient statistical power. 
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In the study of prognostic markers, 63 frozen tissue samples were left after matching 
for the tumor progression status (T=2) and histological filtering to intestinal-type 
gastric cancers. This can be regarded a high sample number, as follow-up clinical 
information (survival data) must be available for patient samples, which is often 
limited in frozen research samples. A similar situation was given in the HER2 
classification study, where HER2 status was only available for few samples. The reason 
is that at the time of my study, the HER2 status was not routinely evaluated in gastric 
cancer patients. 
Finally, one important aim was to test the results on an independent patient set in 
order to confirm their validity and reproducibility [90]. For validation of the proposed 
markers, immunohistochemistry was performed on large patient cohorts using tissue 
microarrays (TMA) [64]. Also here, the selection of samples was performed carefully. 
In collaborative research, I also aimed to find clinically relevant markers in colon and 
Barrett’s cancer. While MALDI imaging was applied in both cancer types to find 
markers for the potential of the tumor to metastasize, epigenetic analyses were 
performed in colon cancer samples only. In the latter, DNA methylation of candidate 
genes was tested for the ability to predict therapy response prediction or to detect the 
presence of tumor precursors. 
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2 Published results 
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2.1 Summary of presented publications 
In the presented publications, matrix-assisted laser desorption/ionization (MALDI) 
imaging mass spectrometry was used for the proteomic analysis of gastric cancer 
tissue samples, with the aim of 
 Identifying proteins that predict disease outcome of patients with intestinal-
type gastric cancer after surgical resection 
 Generating a proteomic classifier that determines HER2-status in order to 
aid in therapy decision with regard to trastuzumab (Herceptin) 
administration. 
In the first study, a seven-protein signature was found to be associated with an 
unfavorable overall survival independent of major clinical covariates after analyzing 63 
intestinal-type primary resected gastric cancer samples by MALDI imaging. Of these 
seven proteins, three could be identified as CRIP1, HNP-1, and S100-A6, and validated 
immunohistochemically on tissue microarrays of an independent validation cohort 
(n=118). While HNP-1 and S100-A6 were found to further subdivide early (UICC-I) and 
late stage (UICC-II-III) patients into different prognostic groups, CRIP1, a protein 
previously unknown in gastric cancer, was confirmed as a novel and independent 
prognostic factor for all patients in the validation cohort. The protein pattern 
described here serves as a new independent indicator of patient survival 
complementing the previously known clinical parameters in terms of prognostic 
relevance.  
In the second study, we hypothesized that MALDI imaging mass spectrometry may be 
useful for generating a classifier that may determine HER2-status in gastric cancer. 
This assumption was based on our previous results where HER2-status could be 
reliably predicted in breast cancer patients [53]. Here, 59 gastric cryo tissue samples 
were analyzed by MALDI imaging and the obtained proteomic profiles were used to 
create HER2 prediction models using different classification algorithms. Astonishingly, 
the breast cancer proteomic classifier from our previous study was able to correctly 
predict HER2-status in gastric cancers with a sensitivity of 65% and a specificity of 92%. 
In order to create a universal classifier for HER2-status, breast and non-breast cancer 
samples were combined, which increased sensitivity to 78%; specificity was 88%. This 
study provides evidence that HER2-status can be identified on a proteomic level across 
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different cancer types suggesting that HER2 overexpression may constitute a widely 
spread molecular event independent of the tumor entity. 
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2.2 Zusammenfassung der veröffentlichten 
Arbeiten 
Im Rahmen dieser Doktorarbeit wurden zwei Arbeiten publiziert, in denen die 
bildgebende Massenspektrometrie als zentrale Methode zur proteomischen Analyse 
von Magenkarzinomgeweben eingesetzt wurde. Dabei wurden folgende Ziele verfolgt:  
 Identifizierung prognostischer Proteinmarker für Patienten mit intestinalem 
Magenkarzinom 
 Generierung eines proteomischen Klassifikators zur Bestimmung des HER2-
Status zur Entscheidungshilfe für eine Behandlung mit Trastuzumab 
(Herzeptin) 
In der ersten Studie wurde eine Signatur bestehend aus sieben Proteinsignalen 
gefunden, deren Überexpression unabhängig von anderen klinischen Parametern ein 
schlechtes Gesamtüberleben der Patienten indizieren. Hierzu wurden 63 
Gewebeproben von Patienten mit Magenkarzinom intestinalen Typs mittels MALDI 
Imaging analysiert. Drei der sieben Proteinsignale konnten als CRIP1, HNP-1 und S100-
A6 identifiziert werden. Diese wurden anschließend an einem unabhängigen 
Patientenkollektiv (n=118) immunhistochemisch anhand von Tissue Microarrays 
validiert. Dabei zeigte sich, dass die beiden Proteine HNP-1 und S100-A6 bestehende 
klinische Gruppen nach ihrem Risiko weiter aufstratifizieren konnten; HNP-1 
Magenkarzinompatienten im frühen Stadium (UICC I) und S100-A6 Patienten im 
fortgeschrittenen Stadium (UICC II-III). Darüber hinaus konnte CRIP1 als unabhängiger 
prognostischer Faktor für alle Patienten des Validierungskollektives bestätigt werden. 
Perspektivisch könnte die hier beschriebene Proteinsignatur vorhandene klinische 
Parameter als neuer und unabhängiger Indikator für das Überleben von 
Magenkrebspatienten ergänzen. 
In der zweiten Studie wurden Proteinexpressionsmuster benutzt, um den HER2-Status 
in Magenkrebsgeweben vorauszusagen; denn seit kurzem ist der epidermale 
Wachstumsfaktor-Rezeptor HER2 eine wichtige tumorbiologische Zielstruktur bei der 
Behandlung von Magenkrebspatienten mit dem therapeutischen Antikörper 
Trastuzumab. In einer vorherigen Studie konnten wir die Machbarkeit der HER2-
Status-Bestimmung durch MALDI Imaging erfolgreich anhand von Brustkrebsproben 
demonstrieren [53]. Unter der Annahme, dass der HER2-Überexpression –  
unabhängig vom Tumortyp – charakteristische molekulare Veränderungen zugrunde 
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liegen, wurde untersucht, ob eine Bestimmung des HER2-Status in 
Magenkrebspatienten mit Hilfe von Proteinexpressionsmustern aus 
Brustkrebspatienten erfolgen kann. Hierzu wurden, zusätzlich zu den bereits 
vorhandenen 48 Brustkrebsgeweben, 59 Magenkrebsfälle mittels MALDI Imaging 
analysiert und verschiedene HER2-Klassifikationsmodelle erstellt und verglichen. Der 
HER2-Status in Magenkrebsfällen konnte mit einem Mammakarzinom-spezifischen 
Profil mit einer Sensitivität von 65% und einer Spezifität von 92% bestimmt werden. 
Zusätzlich wurden die Expressionsprofile aller vorhandenen Tumorarten 
zusammengeführt, um einen universellen HER2-Klassifikator zu erstellen. Dies führte 
zu einer verbesserten Vorhersagequalität (Sensitivität: 78%, Spezifität: 88%). Dass sich 
der HER2-Status über verschiedene Tumorentitäten hinweg auf proteomischer Ebene 
bestimmen lässt, legt nahe, dass die Überexpression von HER2 ein unabhängiges 
molekulares Ereignis darstellt, ungeachtet der Herkunft des Tumors. Zudem 
unterstreichen die Ergebnisse das diagnostische Potential der bildgebenden 
Massenspektrometrie zur schnellen und zuverlässigen Bestimmung von 
tumorbiologischen Zielstrukturen, wie HER2. 
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2.3 MALDI imaging identifies prognostic seven-
protein signature of novel tissue markers in 
intestinal-type gastric cancer 
 
Balluff B, Rauser S, Meding S, Elsner M, Schöne C, Feuchtinger A, Schuhmacher C, 
Novotny A, Jütting U, Maccarrone G, Sarioglu H, Ueffing M, Braselmann H, 
Zitzelsberger H, Schmid RM, Höfler H, Ebert MP, and Walch A.  
Am J Pathol. 2011 Dec;179(6):2720-9. 
 
2.3.1 Journal description and standing 
The American Journal of Pathology (ISI abbreviation: Am J Pathol) publishes papers on 
the cellular and molecular biology of diseases. Focus is given on work that advances 
basic and translational knowledge of the pathogenesis, classification, diagnosis, and 
mechanisms of diseases, with preference for studies which consider morphology. 
The American Journal of Pathology is indexed by Thomson Reuters in the category 
Pathology. With an impact factor of 5.224 and a 5-year impact factor of 5.971 in the 
2010 Journal Citations Reports it takes rank four of 76 journals within its category.  
 
2.3.2 Abstract 
Proteomics-based approaches allow us to investigate the biology of cancer beyond 
genomic initiatives. We used histology-based matrix-assisted laser 
desorption/ionization (MALDI) imaging mass spectrometry to identify proteins that 
predict disease outcome in gastric cancer after surgical resection. 
A total of 181 intestinal-type primary resected gastric cancer tissues from two 
independent patient cohorts were analyzed. Protein profiles of the discovery cohort 
(n=63) were directly obtained from tumor tissue sections by MALDI imaging. A seven-
protein signature was found to be associated with an unfavorable overall survival 
independent of major clinical covariates (HR=4.03; 95% CI: 1.69 - 9.61; P=0.002). The 
prognostic significance of three individual proteins identified (CRIP1, HNP-1, and S100-
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A6) was validated immunohistochemically on tissue microarrays of an independent 
validation cohort (n=118). While HNP-1 and S100-A6 were found to further subdivide 
early (UICC-I) and late stage (UICC-II-III) patients into different prognostic groups 
(P=0.024, P=0.013), CRIP1, a protein previously unknown in gastric cancer, was 
confirmed as a novel and independent prognostic factor for all patients in the 
validation cohort (HR=1.57; 95% CI: 1.01-2.44; P=0.044). 
The protein pattern described here serves as a new independent indicator of patient 
survival complementing the previously known clinical parameters in terms of 
prognostic relevance. These results show that this tissue-based proteomic approach 
may provide clinically relevant information that might be beneficial in improving risk 
stratification for gastric cancer patients. 
 
2.3.3 Introduction 
Although the incidence of gastric cancer has declined worldwide over the past 30 
years, especially in Western countries, it remains the second leading cause of cancer-
related death and accounts for 9.7% of cancer deaths globally [3, 91]. Despite complex 
treatment regimens and further understanding of its biology and possible causes, 
surgery is the only potentially curative treatment for gastric cancer [92]. Patients with 
stage I disease have a good prognosis, whereas those with stage IV disease show a 
poor prognosis. Interestingly, the prognosis varies widely in patients with stage II or III 
disease for as of yet undetermined biologic reasons [93]. 
The clinical and biological behavior of individual gastric cancer patients cannot be 
understood through the analysis of individual or small numbers of genes, so cDNA 
microarray analysis has been used with some success to simultaneously investigate 
thousands of RNA expression levels and attempt to identify patterns associated with 
biological characteristics [94-96]. However, mRNA expression is often poorly 
correlated with levels of protein expression, and such analyses cannot detect 
important post-translational modifications of proteins such as proteolytic processing, 
phosphorylation, or glycosylation, all of which are important processes in determining 
protein function [97]. Accordingly, comprehensive analysis of protein expression 
patterns might improve our ability to understand the molecular complexities of tumor 
tissues. 
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Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry, or 
MALDI imaging, is a powerful tool for investigating protein patterns through the direct 
(in situ) analysis of tissue sections [5]. Similarly to immunohistochemistry, MALDI 
imaging has advantages over other assay methods (i.e., those requiring 
homogenization) because it is morphology driven [98]. This characteristic allows to 
directly evaluate tumor cells, to determine correlations with other morphologic 
features, and to assay smaller patient tumor tissue specimens, such as surgical or 
endoscopic biopsy specimens [79]. These features make it an interesting tool for tissue 
analysis and molecular histology [99]. In addition, MALDI imaging can determine the 
distribution of hundreds of compounds in a single measurement without any need for 
labeling [100]. The great potential of a highly sensitive and molecularly specific 
technology such as MALDI imaging to the field of oncology is currently being realized. 
Until now, this technique has been successfully applied to various types of cancer 
tissues, including human non-small cell lung cancer, gliomas, and ovarian, prostate, 
and breast cancer [69, 70, 72, 101-103]. Analysis of the resulting complex mass 
spectrometry data sets using modern biocomputational tools has resulted in the 
identification of both disease state, response prediction, and patient prognosis-
specific protein patterns [69-71]. 
To explore the possibility of using tissue-based proteomic analysis as a predictor of 
outcome in resected gastric cancer, we used MALDI imaging for direct tissue analysis 
of protein expression to identify proteins that predict disease outcome in patients 
with intestinal gastric cancer. 
 
2.3.4 Material and methods 
Study Population and Tissues 
All tissues investigated in this study were obtained from patients (n=181) who 
underwent gastrectomy between 1991 and 2005 at the Surgery Department at the 
Technische Universität München. Histological classification was performed according 
to the WHO and the TNM classification systems designed by the International Union 
Against Cancer (UICC) [23, 104]. All tumors analyzed in this study were intestinal type 
tumors according to Lauren’s classification system [24]. Follow-up data were available 
for all patients, and the overall survival was calculated from the date of surgical 
resection to the date of death or last follow-up. This study was approved by the 
Institutional Review Board and the Ethics Committee of the Faculty of Medicine of the 
41 
 
Technische Universität München with informed consent from all subjects and patients. 
The clinicopathological data of all patients are listed in Table 2-1. 
Table 2-1 Correlation of spectral features and their respective identified proteins with 
clinicopathological parameters for the patient series 
  Discovery cohort (n=63) Validation cohort (n=118) 
   MALDI imaging m/z signals  Immunohistochemistry antigens 
  No. of 
patients 
3445 6278 8406 8453 10098 11353 11613 No. of 
patients 
HNP-1 CRIP1 S100-A6 
  (HNP-1)  (CRIP1)  (S100-A6)   (m/z 3445) (m/z 8406) (m/z 10098) 
Sex *  0.257 0.348 0.953 0.383 0.002 0.579 0.951  0.448 0.092 0.259 
 Male 46        89    
 Female 17        29    
Age †  0.114 0.220 0.159 0.564 0.039 0.290 0.947  0.009 0.152 0.678 
Primary tumor †  — — — — — — —  0.248 0.375 0.224 
 pT1 0        15    
 pT2 63        54    
 pT3 0        44    
 pT4 0        5    
Regional lymph nodes †  0.730 0.572 0.059 0.396 0.081 0.400 0.305  0.016 0.964 0.023 
 pN0 18        36    
 pN1 24        35    
 pN2 16        35    
 pN3 5        9    
 pNx 0        3    
Distant metastasis ‡  0.976 0.321 0.089 0.687 0.005 0.036 0.616  0.517 0.779 0.038 
 M0 54        87    
 M1 9        31    
Resection 
status ‡  0.675 0.238 0.055 0.129 0.011 0.448 0.150  0.196 0.624 0.361 
 R0 53        81    
 R1 9        26    
 Rx 1        11    
Grading †  0.389 0.685 0.720 0.389 0.227 0.033 0.104  0.168 0.388 0.018 
 G1 0        1    
 G2 16        36    
 G3 47        81    
Overall survival §  0.075 0.009 0.018 0.022 0.013 0.012 0.026  0.086 ¶ 0.016 0.077 ** 
Bold print values indicate that the P value is < 0.05. 
* P value calculated by t-test. 
† P value calculated by Spearman’s rank correlation. 
‡ P value calculated by Mann-Whitney U test. 
§ P value calculated by univariate Cox proportional hazard regression. 
¶ Union Internationale Contre le Cancer (UICC) stage I. 
** UICC stages II and III. 
 
Discovery cohort  
Fresh-frozen tissue samples were obtained from 63 primary resected gastric 
carcinoma patients that were matched to UICC-T status (T=2). Patients were on 
average 66.5 years old (range: 33–85), and their median overall survival time was 33.1 
months (range: 0–53.4). The tissues were snap-frozen and stored in liquid nitrogen. 
This discovery cohort was used for tissue-based proteomic analysis by MALDI imaging. 
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Validation cohort  
The patient cohort of the validation set was comprised of 118 tumor samples and was 
provided in triplicate in formalin-fixed paraffin-embedded tissue microarrays from the 
Institute of Pathology of the Technische Universität München. The clinicopathological 
data of this independent sample set are also included in Table 2-1. The patients’ 
median overall survival time was 54.7 months (range: 0–135.5), and their mean age 
was 66.4 years (range: 41–80). The validation of the proteins was performed in this 
independent patient cohort by immunohistochemical analyses. 
MALDI imaging for the discovery of survival-related proteins 
Frozen tissue sections from the discovery cohort were cut on a cryostat (CM1950, 
Leica Microsystems, Wetzlar, Germany) at a 12 µm thickness onto indium-tin-oxide 
coated glass slides (Bruker Daltonics, Bremen, Germany). After brief washing in both 
70% and 100% ethanol pro analysis solutions, slides were coated with sinapinic acid 
matrix solution (Sigma-Aldrich, Taufkirchen, Germany) at 10 mg/ml in 
water/acetonitrile 40:60 (v/v) with 0.2% trifluoroacetic acid pro analysis (TFA) by an 
automated spraying device (ImagePrep, Bruker Daltonics).  
For mass spectrometric measurements, tumor areas were defined using the 
FlexControl 3.0 and FlexImaging 2.1 software packages (both Bruker Daltonics). 
Spectra were acquired using the Ultraflex III MALDI-TOF/TOF (Bruker Daltonics) in 
positive linear mode, whereas ions were detected in a mass range of m/z 2,500–
25,000 with a lateral resolution of 70 µm. A ready-made protein standard was 
employed for spectra calibration (Bruker Daltonics).  
Following the MALDI experiments, the glass slides were incubated in 70% ethanol to 
elute the matrix and then stained with hematoxylin and eosin. Finally, the stained 
slides were scanned with a digital slide scanning system (Mirax Desk, Carl Zeiss 
MicroImaging, Göttingen, Germany) and co-registered to the MALDI imaging results to 
align mass spectrometric data with the histological features of the very same sections. 
Tumor specific spectra were selected using the FlexImaging software (Bruker 
Daltonics). Eighty spectra per case were picked randomly and were imported into the 
ClinProTools 2.2 software (Bruker Daltonics), upon which the data underwent 
normalization, recalibration (both to enable comparability of measurements), and 
peak picking. After processing, the data were exported for further statistical analyses. 
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Protein identification 
Ten cryosectioned slices (25 µm each) of three different tissue specimens underwent 
protein extraction with aqueous 0.1% TFA and ultrasonication. The extracted proteins 
were separated on an mRP-C18 column (Agilent Technologies, Santa Clara, CA, USA), 
and the fractionated aliquots were collected in a 96-well-plate. The HPLC fractions 
were manually spotted onto a PAC target (Bruker Daltonics) and analyzed by MALDI-
MS (Ultraflex I, Bruker Daltonics) in order to locate fractions containing the m/z 
species of interest. Fractions of interest underwent tryptic digestion, and the resulting 
peptides were separated on a nano-RP-HPLC column (PepMap, LC Packings, 
Sunnyvale, CA, USA), which was connected to a linear quadrupole ion trap mass 
spectrometer (LTQ Orbitrap XL, Thermo Scientific, Waltham, MA, USA) equipped with 
a nano-ESI ion source. All obtained MS/MS spectra were searched in the NCBInr 
human sequence database using Mascot (v2.2.06, Matrix Science, London, UK). The 
final evaluation of the protein/peptide identification results was done using the 
Scaffold 3 software framework (Proteome Software, Portland, OR, USA). 
Validation of proteins by immunohistochemistry 
Immunohistochemical staining of the 3 µm tissue microarray sections was carried out 
using an automated stainer (Discovery XT) and a DAB Map kit (both, Ventana Medical 
Systems, Tucson, AZ, USA). The dilutions used for primary antibodies against HNP-1 
(BMA Biomedicals, Augst, Switzerland), CRIP1 (AbD Serotec, Oxford, UK), and S100-A6 
(Thermo Scientific) were 1:400, 1:100, and 1:100, respectively.  
The analysis of the immunohistochemical staining was conducted with an image 
analysis platform (Definiens Enterprise Image Intelligence Suite, Definiens AG, Munich, 
Germany). For this purpose, all stained slides were scanned at 20X objective 
magnification by a digital slide scanner (Mirax Desk, Carl Zeiss MicroImaging), and the 
images were imported into the image analysis software. Specific rule sets were then 
defined to detect and quantify the immunohistochemical staining intensities of 
semantic classes. While the quantified parameter for CRIP1 and S100-A6 staining was 
the brown intensity of the tumor cells, the area of the peptide expressing granulocytes 
was the quantified parameter for HNP-1. 
Statistical Analysis 
Correlations between the investigated parameters and clinicopathological features 
were determined as outlined in Table 2-1. 
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M/z species associated with overall survival, obtained by MALDI imaging, were 
identified by corrected multiple testing using the Significance Analysis of Microarrays 
(SAM) package with a maximum false discovery rate of 0.1 [105]. To investigate the 
predictive power of the combined MALDI imaging signals, all patients were clustered 
into two groups by hierarchical clustering. The dendrogram was calculated using the 
Ward linkage method based on a weighted Euclidean distance. Each weight 
corresponded to the reciprocal of the respective m/z species' univariate P value. The 
correct classification rate of this protein pattern to one of the groups was tested by 
establishing a classification model based on a support vector machine, running with 
standard parameters (kernel=radial, cost=1) and a 10-fold cross-validation. 
Multivariate analyses for the assessment of clinical parameter influences were done 
by Cox regression with p-values calculated by the Wald test. Kaplan-Meier curves were 
calculated by defining favorable and unfavorable prognostic groups using an intensity-
based threshold score, which maximized overall survival differences between both 
respective groups while minimizing imbalances in group sizes. Differences between 
the curves were assessed using the log-rank test. 
All statistical analyses were performed within the R statistical environment (R 
Foundation for Statistical Computing, Vienna, Austria), in which P values <0.05 were 
considered statistically significant and values between 0.05 and 0.1 were considered 
trends. 
 
2.3.5 Results 
MALDI imaging reveals seven survival-associated proteins 
To detect protein signals associated with overall survival in gastric cancer, we acquired 
the cancer protein profiles of 63 patients utilizing MALDI imaging mass spectrometry 
in the discovery cohort. This strategy allowed the histology-directed acquisition of 
cancer cell-specific protein spectra from the measured tissue samples. On average, we 
could resolve between 150 and 200 peaks per case within the mass range of m/z 2,500 
to 25,000 and a mass accuracy of +/-3 m/z. For example, a representative tumor peak 
(m/z species) and the morphological features of an individual patient’s tissue sample 
are shown in Figure 2-1. 
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Figure 2-1 MALDI imaging reveals cell type-specific profiles, as shown in this comparison of 
gastric carcinoma (red) and normal gastric mucosa (green) from an individual patient’s tissue. 
In this study, one example of differentially expressed masses (m/z 8406), exclusively present in 
cancer cells (right insert, red visualization), was found to correlate significantly with the 
patients’ overall survival. 
After setting the false discovery threshold to 0.1 and excluding correlated features, we 
found seven m/z species at an average of m/z 3445, m/z 6278, m/z 8406, m/z 8453, 
m/z 10098, m/z 11353, and m/z 11613, which were associated with patient survival 
(see Supplemental Figure 2-1). Correlations to clinicopathological parameters are 
listed in Table 2-1. 
The influence of each m/z species on survival was then studied in more detail. 
Univariate Cox regression showed that, with the exception of m/z 3445 (P=0.075) 
which indicates a prognostic trend, all signals exhibit a strong non-favorable effect on 
survival. M/z 6278 (P=0.009) has the highest prognostic value, followed by m/z 11353 
(P=0.012), m/z 10098 (P=0.013), m/z 8406 (P=0.018), m/z 8453 (P=0.022), and m/z 
11613 (P=0.026) (Table 2-1). Setting intensity thresholds for each single m/z signal 
resulted in poor and good prognosis groups which all differed significantly in terms of 
overall survival (all P<0.05). A selection of Kaplan-Meier graphs for the long-and short-
46 
 
term survivor groups are depicted in Figure 2-2, A and B, and Figure 2-3, A (for all 
Kaplan-Meier graphs see Supplemental Figure 2-2). 
Multivariate Cox regression models of each respective m/z species, with nodal and 
resection status as well as distant metastasis status as covariables, showed that m/z 
6278, m/z 8453, m/z 10098, and m/z 11613 are independent prognostic factors (all 
P<0.05), whereas m/z values of 3445 (P=0.063) and 8406 (P=0.07) showed slight 
dependencies (Table 2-2). In contrast, m/z 11353 does not exert an independent 
influence on survival (P=0.16).  
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Figure 2-2 M/z 3445 and 10098, as measured by MALDI imaging and identified as HNP-1 and 
S100-A6 correlate with the survival of patients (A, B). Kaplan-Meier analyses in the 
immunohistochemical validation confirmed their prognostic value, although this effect was 
only observed in UICC-stage I patients (C, n=29) for HNP-1 and in UICC-stages II-III for S100-A6 
(D, n=68). 
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Table 2-2 Multivariate survival analyses 
    Covariable Hazard ratio 95% Confidence interval P value 
MALDI imaging    
 m/z 3445 (HNP-1) 1.032 0.998 - 1.070 0.063 
  Nodal status 2.304 1.382 - 3.840 0.001 
  Distant metastasis 0.724 0.163 - 3.220 0.670 
   Resection status 1.398 0.273 - 7.160 0.690 
 m/z 6278 1.332 1.088 - 1.630 0.006 
  Nodal status 2.869 1.661 - 4.960 0.000 
  Distant metastasis 0.661 0.165 - 2.640 0.560 
   Resection status 0.531 0.092 - 3.080 0.480 
 m/z 8406 (CRIP1) 1.458 0.970 - 2.190 0.070 
  Nodal status 2.477 1.459 - 4.210 0.001 
  Distant metastasis 0.521 0.109 - 2.490 0.410 
   Resection status 0.772 0.116 - 5.160 0.790 
 m/z 8453 3.626 1.275 - 10.31 0.016 
  Nodal status 2.579 1.527 - 4.360 0.000 
  Distant metastasis 0.760 0.185 - 3.130 0.700 
   Resection status 0.643 0.121 - 3.420 0.600 
 m/z 10098 (S100-A6) 1.219 1.012 - 1.470 0.037 
  Nodal status 2.522 1.469 - 4.330 0.001 
  Distant metastasis 0.407 0.078 - 2.130 0.290 
   Resection status 1.042 0.171 - 6.350 0.960 
 m/z 11353 1.177 0.939 - 1.480 0.160 
  Nodal status 2.091 1.231 - 3.550 0.006 
  Distant metastasis 0.585 0.138 - 2.480 0.470 
   Resection status 1.668 0.326 - 8.530 0.540 
 m/z 11613 1.694 1.082 - 2.650 0.021 
  Nodal status 2.570 1.529 - 4.320 0.000 
  Distant metastasis 0.584 0.121 - 2.820 0.500 
   Resection status 0.867 0.137 - 5.470 0.880 
 Seven-protein signature 4.031 1.691 - 9.610 0.002 
  Nodal status 2.501 1.521 - 4.110 0.000 
  Distant metastasis 0.725 0.183 - 2.870 0.650 
    Resection status 1.165 0.260 - 5.220 0.840 
Immunohistochemistry    
 CRIP1 (m/z 8406) 1.570 1.012 - 2.440 0.044 
  Primary tumor 1.660 0.939 - 2.950 0.081 
  Nodal status 1.670 1.045 - 2.670 0.032 
  Distant metastasis 1.090 0.437 - 2.720 0.860 
   Resection status 1.030 0.363 - 2.950 0.950 
 S100-A6 (m/z 10098) * 3.800 1.130 - 12.81 0.031 
  Primary tumor 1.720 0.611 - 4.860 0.300 
  Nodal status 2.190 0.865 - 5.570 0.098 
  Distant metastasis 1.120 0.310 - 4.050 0.860 
  Resection status 1.670 0.355 - 7.830 0.520 
Data are calculated by Cox proportional hazard regression. Bold print indicates that the P value is < 0.05. 
*Union Internationale Contre le Cancer (UICC) stages II and III only. 
 
Identification of three survival-related protein markers: HNP-1, CRIP1, and 
S100-A6 
Protein identification of m/z 3445 was performed by tissue extraction and 
fractionation followed by bottom-up tandem mass spectrometry. Human neutrophil 
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peptide-1 (HNP-1) was identified with a Mascot Score of 109. Protein scores above 56 
indicate identity or extensive homology (P<0.05) (see Supplemental Figure 2-3). 
Additionally, this mass has already been reported as HNP-1 in several other studies 
[71].  
Signal m/z 8406 (+/-3 m/z) has previously been identified by our group as Cysteine-
rich intestinal protein 1 (CRIP1) [53]. Similarly, the signal at m/z 10098 corresponds to 
the calcium binding protein, S100-A6, as previously shown by Schwartz et al. [70] 
The other four molecular species have remained unidentified and require further 
elucidation efforts.  
Validation on an independent patient cohort by immunohistochemistry 
confirms the prognostic relevance of the identified protein markers 
Based on the results of the discovery study, we validated the predictive power of the 
identified proteins CRIP1, S100-A6, and HNP-1 using an independent test cohort 
comprised of 118 patients. 
Although univariate analysis indicated a significant correlation of CRIP1 (P=0.016) on 
patient survival for all UICC stages, slight associations were found for HNP-1 and S100-
A6 for certain subgroups. S100-A6 slightly reflected the survival in UICC stages II-III 
(P=0.077) and HNP-1 slightly the survival in UICC stage I patients (P=0.086). These 
findings are in line with the Kaplan-Meier analyses, as shown in Figure 2-2. Next, the 
global prognostic value of CRIP1 was further investigated in a multivariate analysis. 
CRIP1 was found to be the strongest variable, besides nodal status (P=0.032), to 
indicate the outcome of patients (P=0.044), therefore confirming its high predictive 
power (Table 2-2). This finding is also shown in the Kaplan-Meier analyses together 
with immunohistochemical examples of low and high expression of CRIP1 in Figure 
2-3. Similarly, S100-A6 has a significant independent effect on the survival of stage II 
and III patients (P=0.031). 
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Figure 2-3 CRIP1, a previously unknown protein in gastric cancer, was found by MALDI imaging 
as a novel prognostic factor in the discovery cohort (A, C). Immunohistochemical validation 
confirmed this by showing a strong relationship between the high expression of CRIP1 (E) and 
poor survival (B) and vice versa (B, D), as calculated by Kaplan-Meier analysis (n=114). 
Seven-protein signature predicts the outcome of patients independently of 
clinical parameters 
To improve prognostic ability further, all seven markers were combined to establish a 
survival prediction model. Therefore, unsupervised clustering was applied to 
discriminate patients into two groups according to their seven-protein signature 
(Figure 2-4, A). The difference in patient outcome between both groups was assessed 
by univariate Kaplan-Meier analysis (P=0.002) (Figure 2-4, B) and multivariate Cox 
regression (P=0.002) (Table 2-2). This analysis indicated the strong predictive value of 
the signature independent of nodal or distant metastasis and resection status.  
The discriminatory power of this pattern (Figure 2-4, C) between the two tumor 
subgroups was assessed by cross-validation of a classification model (support vector 
machine), which achieved a classification accuracy of 98% (95% CI: 91% to 100%). 
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A combination of mass signals representing the three identified proteins was found 
sufficient to be a significant indicator for patient survival, and even independent from 
clinical parameters. However, the full signature adds significantly more prognostic 
information (see Supplemental Figure 2-4). 
 
Figure 2-4 The prognostic power of a combined pattern was investigated by clustering all 
patients according to the seven protein signals (A, C). The main two branches of the tree were 
found to represent a good (blue) and a poor prognosis group (red) (B). Moreover, this pattern 
predicts patient outcome independently of major clinicopathological parameters (Table 2-2). 
 
2.3.6 Discussion 
Previous studies have defined prognostic subsets of gastric cancer based on gene or 
microRNA expression patterns [94-96, 106]. However, mRNA expression cannot 
always indicate which proteins are expressed or how their activity might be 
modulated after translation [107, 108]. Accordingly, analysis of the proteome in tumor 
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tissues might better reflect the underlying pathological state of cancers than gene 
expression patterns. A few tissue-based reports in gastric cancer have shown that 
proteomic patterns with surface-enhanced laser desorption/ionization-TOF can 
distinguish cancer patients from non-cancer patients [109, 110]. A very recent report 
in gastric cancer demonstrated that protein profiles obtained from endoscopic biopsy 
samples via MALDI imaging can distinguish pathologic early stage tumors from more 
advanced tumors [79]. However, none of the mentioned studies performed prognostic 
evaluations of the protein patterns. This study is the first to show that tissue-based 
proteomic profiling by MALDI imaging is able to identify protein patterns that predict 
patient survival in intestinal-type gastric cancer. Previously known and, more 
importantly, previously unknown protein biomarkers were identified, amongst them 
HNP-1, CRIP1, and S100-A6. Interestingly, both HNP-1 and CRIP1 have been described 
in the context of the immune system [111, 112]. It is known from clinical and 
experimental studies that the immune system is a significant determinant of epithelial 
tumorigenesis and further development [113]. 
Cysteine-rich intestinal protein 1 (CRIP1), a so far unknown protein in gastric cancer, 
was found in this study as an independent prognostic factor in the validation cohort 
(Table 2-2). Human CRIP1 belongs to the LIM family and is a tissue-specific 
developmentally regulated protein which is involved in protein–protein interactions 
during transcription [114-117]. CRIP1 has been suggested to play a role in the host 
defense system, too, and differential expression of CRIP1 can change cytokine 
patterns and the immune response [112]. In this context, an elevated level of CRIP1 in 
tumor cells may be sensible as it has been proposed that immune cells are actively 
recruited by tumors to exploit their pro-angiogenic and pro-metastatic effects. This is 
supported by gene expression analyses where mRNA of CRIP1 has been found to be 
overexpressed in various tumor types, including colorectal, pancreatic, prostate, 
breast, and cervical cancers [118-122]. However, this is the first study that describes 
CRIP1 to affect patient survival. No other significant correlations to major clinical 
parameters were found for CRIP1 in our study. Since the functional characterization of 
CRIP1 is currently inadequate, the precise role of CRIP1 in cancer cells is unclear and 
requires further investigation. 
HNP-1 is an antimicrobial peptide that is expressed in human neutrophils of the innate 
immune system and found to be present in a variety of tumor types, including gastric 
and colon cancer [110, 111, 123]. The link between a chronic active inflammatory 
process, where neutrophils make up a significant portion of the inflammatory cell 
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infiltrate, and the onset of carcinoma has been convincingly demonstrated at the 
gastric and intestinal mucosal level [124]. It has been shown in cancers that a strong 
presence of infiltrating innate immune cells, such as neutrophils, correlates with 
increased angiogenesis and poor prognosis, whereas an abundance of infiltrating 
lymphocytes correlates with favorable prognosis [113]. This is reflected in several 
serum based studies that investigated the ratio between neutrophils and lymphocytes 
in different cancer types like in renal cell carcinoma or breast cancer [125, 126]. 
However, this study is the first to show the prognostic significance of HNP-1 in gastric 
cancer tissues. The results of this study underscore the assumptions that the immune 
system and associated proteins, represented here by HNP-1 and CRIP1, take a key role 
in tumor behavior and therefore clinical outcome for the patients. 
In contrast, S100-A6, a calcium binding protein, has not been reported to be linked to 
the immune system. Amongst many versatile functions of S100-A6, it has been mainly 
described to be involved in cytoskeleton rearrangement since actin binding proteins, 
like annexins, have been identified as its target (see Supplemental Figure 2-5) [127]. In 
this context, interactions with tumor associated proteins like annexin A2 and p53 may 
indicate a role of S100-A6 in cancer progression and metastasis [128, 129]. And 
indeed, increased levels of S100-A6 have been found to be associated with metastasis 
or survival in colon and pancreatic cancer, respectively [130, 131]. Similarly, our study 
showed a significant correlation of S100-A6 expression with clinical parameters such 
as regional lymph node metastasis, distant metastasis, tumor cell differentiation, and 
prognosis. This is highly concordant with a recent study in gastric cancer 
demonstrating the association between S100-A6 expression and various 
clinicopathological features including clinical patient outcome [132]. Unfortunately, 
little is still known about the exact mechanism of S100-A6 with regard to an aggressive 
tumor phenotype. Nevertheless, our observations support the general findings that 
S100-A6 plays an important role in the progression and prognosis in gastric cancer 
patients. 
The other four molecular species have remained unidentified so far and require 
further elucidation efforts. Since there is so far no universal strategy in MALDI imaging 
proteomics for identifying the molecular nature of a peak, each protein requires an 
individual identification approach and elaborate protocol adaptations [60, 133]. 
We shifted the emphasis of our study to the combination of these molecular species 
that are directly related to prognosis as it has been reported that individual markers 
may vary for a variety of reasons, but at a statistically significant level, a signature 
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would remain more robust [57]. The seven-protein signature described was found to 
be a new independent indicator of patient survival and may complement the 
previously known clinical parameters such as lymph node metastasis and stage in 
terms of prognostic relevance.  
Importantly, the amount of tissue required for MALDI imaging is much smaller than 
any other available method using molecular profiling techniques such as array-based 
gene expression profiling. Thus, our study shows that protein profiles can be obtained 
from smallest amounts of unprocessed fresh frozen tissue samples, which are readily 
collectable in a clinical setting, to accurately predict prognosis. Since such small tissue 
samples can be used, it would be of great interest to analyze the protein expression 
patterns of tissue samples from small endoscopic biopsies or attempt to derive 
patterns associated with response to specific treatments and correlate these findings 
with the risk of progression to cancer. If these data are confirmed in larger numbers of 
patients, tissue-based proteomics profiling by MALDI imaging could have implications 
for the clinical management of patients with gastric cancer. 
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2.3.7 Supplementary material 
Supplemental Figure 2-1 
 
Supplemental Figure 2-1 A: Significance Analysis of Microarrays (SAM) plot. Circles in plot 
represent individual m/z species. Dashed lines delimit the area of random effect. Red circles 
indicate that higher expression correlates with a higher risk. The inset lists the m/z species 
together with their individual q-values (indirectly related to the false discovery rate, which was 
set to a maximum of 10%). B: Correlation coefficients between m/z species. Correlation 
coefficients were calculated by Spearman's rank correlation. Values above 0.8 were considered 
highly correlated. Thus, the correlated signals with the lower q-values (m/z 6226, m/z 8418, 
and m/z 11,655) were excluded from further consideration. 
56 
 
Supplemental Figure 2-2 
 
Supplemental Figure 2-2 Kaplan-Meier graphs for MALDI imaging m/z species 3445, 6278, 8406, 
8453, 10098, 11353, and 11613. 
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Supplemental Figure 2-3 
 
Supplemental Figure 2-3 Fragment spectra of HNP-1 identification. Neutrophil defensin 1 was 
identified with a Mascot score of 109 (P < 0.05). Neutrophil defensin 1 is cleaved into the 
peptides HNP-1 or HNP-2 (see Uniprot entry: P59665). HNP-2 differs from HNP-1 by the 
absence of one amino acid residue. Theoretical mass calculations from the resulting peptides 
identified m/z 3445 as HNP-1 and m/z 3373 as HNP-2. 
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Supplemental Figure 2-4 
 
Supplemental Figure 2-4 Comparison of seven- and three-signal protein signature. Seven-signal 
(left) and three-signal (right) protein signatures obtained by MALDI imaging were compared 
with regard to their prognostic information. Therefore, patients were first clustered on basis of 
the respective signature (upper panels: see Materials and Methods in main manuscript) and 
the resulting groups were then compared by Kaplan-Meier analyses (lower panels) (A). 
Multivariate survival analyses by COX regression were performed in the MALDI imaging data 
set to assess the prognostic value of the three-signal protein signature in comparison with 
major clinical parameters (B, top) and with the seven-signal signature (B, bottom). Both 
analyses show that the three-protein signature is sufficient to be a significant indicator for 
patient survival, and even independent from clinical parameters. However, the full signature 
adds significant prognostic information. 
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Supplemental Figure 2-5 
 
Supplemental Figure 2-5 Known and predicted interactions of S100-A6 (S100A6) with other 
proteins. This functional protein association network was obtained by searching the STRING 
online database (http://string-db.org) for the entry “S100A6,” Interestingly, S100-A6 binds 
directly to proteins such as p53 (TP53) and annexin 2 (ANXA2), which have been extensively 
described in the context of cancer. 
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2.4 Classification of HER2/neu status in gastric 
cancer using a breast-cancer derived proteome 
classifier 
 
Balluff B, Elsner M, Kowarsch A, Rauser S, Meding S, Schuhmacher C, Feith M, 
Herrmann K, Röcken C, Schmid RM, Höfler H, Walch A, and Ebert MP. 
J Proteome Res. 2010 Dec 3;9(12):6317-22.  
Reproduced with permission from the American Chemical Society, Copyright 2010. 
 
2.4.1 Journal description and standing 
The Journal of Proteome Research (ISI abbreviation: J Proteome Res) publishes content 
encompassing all aspects of global protein analysis and function, emphasizing the 
synergy between physical and life sciences resulting in a multidisciplinary approach to 
the understanding of biological processes.  
The journal is indexed by Thomson Reuters in the category Biochemical Research 
Methods. With an impact factor of 5.460 and a 5-year impact factor of 5.617 in the 
2010 Journal Citations Reports it takes rank nine of 71 journals within its category. 
However, it ranks second in journals focusing on proteomics topics. 
 
2.4.2 Abstract 
HER2-testing in breast and gastric cancers is mandatory for the treatment with 
trastuzumab. We hypothesized that imaging mass spectrometry (IMS) of breast 
cancers may be useful for generating a classifier that may determine HER2-status in 
other cancer entities irrespective of primary tumor site. 
A total of 107 breast (n=48) and gastric (n=59) cryo tissue samples were analyzed by 
IMS (HER2 was present in 29 cases). The obtained proteomic profiles were used to 
create HER2 prediction models using different classification algorithms. 
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A breast cancer proteome derived classifier, with HER2 present in 15 cases, correctly 
predicted HER2-status in gastric cancers with a sensitivity of 65% and a specificity of 
92%. In order to create a universal classifier for HER2-status, breast and non-breast 
cancer samples were combined, which increased sensitivity to 78%, specificity was 
88% respectively. 
Our proof of principle study provides evidence that HER2-status can be identified on a 
proteomic level across different cancer types suggesting that HER2 overexpression 
may constitute a unique molecular event independent of the tumor site. Furthermore, 
these results indicate that IMS may be useful for the determination of potential 
drugable targets, as it offers a quicker, cheaper and more objective analysis than the 
standard HER2-testing procedures immunohistochemistry and fluorescence in situ 
hybridization. 
 
2.4.3 Introduction 
Overall prognosis in patients with advanced gastric cancer is poor [134]. Recently, 
Bang and coworkers reported the first results from a phase III trial which compared a 
systemic chemotherapy with cisplatin and capecitabine with and without trastuzumab 
in patients overexpressing human epidermal growth factor receptor 2 (HER2) in gastric 
cancers [33]. In this trial, patients with trastuzumab exhibited a significant 
improvement of progression free and overall survival. This is the first phase III trial 
demonstrating the efficacy of a targeted drug in a subgroup of gastric cancers 
exhibiting overexpression of the respective target [135]. 
In this context, the identification of drugable targets in this and other cancers is an 
important approach in order to develop new treatment strategies [136]. Inasmuch as 
numerous trials with all types of targeted drugs are now being conducted in almost all 
cancer types, identifying a strategy to find and rapidly confirm the presence of 
(multiple) targets in a cancer sample may facilitate the selection of the targeted drug 
that can be successfully administered. 
Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) 
allows the specific acquisition of proteomic profiles from histopathological interesting 
features like tumor cell populations through the direct analysis of thin tissue sections 
[137]. In recent years, IMS has been used to profile different cancers and has been 
shown to allow for the classification of different clinical features of cancers, such as 
62 
 
prognosis, lymph node metastasis and response prediction [69, 72, 99, 138-140]. 
Recently, we demonstrated that this modality can also be used to identify a proteomic 
signature that separates breast cancers based on HER2 status [53]. These findings 
underscored the potential of IMS in tissue diagnostics, especially since the two 
standard procedures for HER2 testing, based on immunohistochemistry (IHC) and 
fluorescence in situ hybridization (FISH), are either less accurate or time and cost 
expensive [50-52]. In contrast, IMS provides an objective classification compared to 
IHC, which suffers from observer variability, while consuming less money and time 
(several hours) compared to FISH (1–2 days). In addition, IMS allows, as a label-free 
and multiplexing approach, to determine several clinical parameters at once.  
In an aim to facilitate the identification and rapid confirmation of potentially drugable 
targets in gastric cancer, we hypothesized that the previously identified breast-cancer 
derived proteomic algorithm may also be able to predict HER2 status in gastric or 
other cancers types. 
 
2.4.4 Material and methods 
Tissue specimens 
Human tissue samples were collected, after obtaining informed consent from patients 
undergoing gastrectomy at the University Hospital of Berlin (gastric cancer test set) 
and the University Hospital of Munich (gastric cancer training set), Germany. Samples 
were snap-frozen during surgery and stored at -80° C until analysis. A total of 59 tissue 
samples, 45 from gastric cancer test set and 14 from gastric cancer training set, were 
analyzed.  
HER2 status was determined in 2000 breast cancer patients. 48 samples of these 
patients were selected for this study according to the following criteria: breast cancer 
of type Invasive Ductal Carcinoma with clear HER2 status, availability of cryo material, 
and strong presence of tumor cell populations in the respective cryo tissue section. 
This set has been previously divided into a discovery (breast cancer training set) and a 
validation set (breast cancer test set), consisting of 30 and 18 cases, respectively [53].  
An overview of all sample sets and the subsequent experimental workflow is depicted 
in Figure 2-5. Clinical and histological characteristics of all patients, including UICC 
staging, Laurén classification, estrogen/progesterone status, and HER2 status are 
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summarized in Table 2-3. This study was approved by the Ethics Committee of the 
Technische Universität München. 
Table 2-3 Clinical and molecular characteristics of the patient series 
Set characteristics Gastric Cancer Breast Cancer 
 
Training set Test set Training set Test set 
Patients 14 45 30 18 
Mean age (range) 64.9 (42–84) 67.9 (40–85) 60.1 (38–91) 61.4 (36–84) 
HER2-IHC 
    
 
IHC 3+/2+ 4/0 4/3 13/2 6/0 
 
IHC 1+/0 1/9 12/26 2/13 6/6 
HER2-FISH 
    
 
positive 4 n.a. 15 n.a. 
 
negative 10 n.a. 15 n.a. 
UICC stage - T 
    
 
pT1 0 1 12 1 
 
pT2 11 21 16 11 
 
pT3 3 18 1 1 
 
pT4 0 5 1 0 
 
pTx 0 0 0 5 
UICC stage - N 
    
 
pN negative 3 4 17 6 
 
pN positive 11 41 12 7 
 
pNx 0 0 1 5 
Laurén type (HER2+) 
    
 
intestinal 10 (4) 28 (4) n.a. n.a. 
 
diffuse 4 (0) 11 (0) n.a. n.a. 
 
mixed 0 6 (0) n.a. n.a. 
ER / PR status 
    
 
ER + n.a. n.a. 14 5 
 
ER - n.a. n.a. 16 13 
 
PR + n.a. n.a. 9 13 
 
PR - n.a. n.a. 21 5 
Abbreviations: HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; FISH 
= ﬂuorescence in situ hybridization; ER = estrogen receptor; PR = progesterone receptor; n.a. = not 
available 
 
Assessment of HER2 status 
HER2 status was evaluated in tumor tissue samples from 2000 breast cancers patients 
and 110 gastric cancer patients by both fluorescence in situ hybridization (FISH) and 
immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tissue blocks. 
Determination of HER2 status was performed according to the guidelines of the 
American Society of Clinical Oncology for HER2 testing for breast cancer, where a 
positive HER2 result is an IHC staining of 3+, a negative result is a staining of 0 or 1+. In 
case a staining was 2+, FISH was performed. A FISH ratio >2.2 (polysomy ratio) is 
considered HER2 positive; otherwise negative [141]. 
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In case paraffin-embedded tissue blocks were not available HER2 status was assessed 
on the respective cryo tissues by IHC only (both test sets), according to the subsequent 
protocol. 10 µm thick sections were incubated with the primary antibody (anti-human 
c-erbB2 polyclonal antibody, Dako Denmark; dilution 1:300) at room temperature for 
one hour. The final immunohistochemical staining was carried out using an automated 
staining platform (Discovery XT, Ventana Medical Systems) according to the 
recommendations of the manufacturer. For cryo section staining, HER2 status was 
regarded positive with an IHC staining of 3+ (uniform membranous staining of >20% of 
tumor cells); conversely, HER2 status was regarded negative if IHC staining was 
classified as 0, 1+, or 2+, as reported by Bang et al. for gastric cancer patients not 
benefitting significantly from HER2 treatment [33]. 
 
Figure 2-5 Experimental workflow. Three cancer (CA) collectives were evaluated for HER2 
expression by IHC and/or FISH (top). Appropriate cryo tissues were subjected to IMS analysis 
(center). For HER2 status prediction, data were arranged in different set-ups, named A–D 
(Table 2-4), into either the training or test set, indicated by dashed lines in orange and green, 
respectively (bottom). 
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MALDI imaging mass spectrometry experiments and image processing 
Tissue samples were cryosectioned (12 µm) onto conductive glass slides and prepared 
for measurement as outlined before [53]. Spectra were acquired using the Ultraflex III 
MALDI-TOF/TOF in positive linear mode (Bruker Daltonik), in a mass range of m/z 
2,500–25,000 and a sampling rate of 0.1 GS/s. The lateral resolution for MALDI-IMS 
was set to 150 µm for the gastric cancer test set and the breast cancer training set. 
The second gastric cancer sample set and the breast cancer validation set were 
measured at 70 µm. 200 laser shots were accumulated per pixel at constant laser 
power. For calibration of spectra a ready-made protein standard was employed 
(Bruker Daltonik).  
Following MALDI-IMS experiments, glass slides were washed for matrix removal in 
70% ethanol, stained with hematoxylin and eosin, and scanned with a digital slide 
scanning system (Mirax Desk, Carl Zeiss MicroImaging). Finally, the tissue scans and 
MALDI-IMS results were superimposed to correlate mass spectrometric data with the 
histological features of the same section. This allowed for a direct, and therefore 
specific, on tissue selection of tumor related mass spectra. 
Data processing and statistical analysis 
Through all patients, spectra associated with tumor areas were selected using the 
FlexImaging 2.1 software (Bruker Daltonik). A total of 400 tumor spectra per patient 
were imported to the ClinProTools 2.2 software for data processing (Bruker Daltonik). 
This processing includes normalization according to the total ion count of each 
spectrum, peak identification, and alignment of spectra to correct for mass shifts 
between measurements.  
For classification and statistical data exploration, the processed data were exported to 
the R statistical software (R Foundation for Statistical Computing). HER2 status 
prediction on cancer samples was implemented using two classification algorithms, 
namely either a Support Vector Machine (e1071 package) or a Random Forest 
(randomForest package). Both classification algorithms have proven their suitability 
for a variety of high-dimensional classification problems in biomedicine, amongst 
others also for proteomic data sets [53, 142-147]. In our study, we explored the ability 
of these classifiers to predict HER2 expression status using different training and test 
set combinations, as listed in Table 2-4. An m/z species was included into the 
prediction model if its area under curve (AUC) exceeded either 0.7 or 0.8, as calculated 
by receiver operating characteristic (ROC) analyses between HER2-positive and HER2-
negative samples in the training set [148]. Moreover, training sets were chosen to 
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have close to equal parts of HER2 positive and negative samples in order to ensure 
sensitivity for infrequent HER2 positivity [149]. 
Due to computational limitations in spectra processing, 40 spectra were selected at 
random for each patient. As the Random Forest algorithm produces non-deterministic 
outcomes [150] and to reduce effects on our results due to random spectra selection, 
we repeated the spectra selection, processing, and classification ten times. Thus, the 
evaluation criteria sensitivity, specificity, accuracy, and their respective confidence 
intervals (CI) were averaged over all ten classification runs for each class prediction 
model. 
Classification models were compared by calculating the Mann–Whitney U test (two-
sided) on the three evaluation criteria across the ten runs. P-values <0.05 were 
considered statistically significant. These results are provided in detail as 
supplementary material. 
 
2.4.5 Results 
Imaging mass spectrometry for HER2 classification on human tissue samples 
Breast cancer samples (training set n=30, test set n=18), and non-breast cancer 
samples (gastric adenocarcinomas; training set n=14, blinded test set n=45) 
underwent mass spectrometric analysis utilizing MALDI-IMS. The obtained mass 
spectra, labeled as either HER2-positive or HER2-negative by IHC and/or FISH, were 
used to arrange training and test set data (see Materials and Methods for a detailed 
description). 
In the following, we report the prediction quality for HER2 status using two 
classification algorithms, namely a Support Vector Machine (SVM) and a Random 
Forest classifier, focusing on the results with an AUC threshold of 0.8 for the feature 
selection (for results with AUC=0.7 see Supplemental Table 2-1). The classification 
models were trained and tested in four different combinations, named A to D as listed 
in Table 2-4. 
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Table 2-4 Training set – test set line-ups 
Setting Training set (HER2+/HER2-) Test set (HER2+/HER2-) 
A Gastric Cancer (4/10) Gastric Cancer (4/41) 
B Breast Cancer (15/15) Gastric Cancer (4/41) 
C Gastric + Breast Cancer (19/25) Gastric Cancer (4/41) 
D Gastric + Breast Cancer (19/25) Gastric + Breast Cancer (10/53) 
Sample sets as referred in Table 2-3 are combined to different training and test set scenarios (A–D). 
The numbers in parenthesis indicate the number of HER2-positive versus HER2-negative samples in 
the respective sets. 
 
In a first attempt (Table 2-4, A), the classifiers should make use of the HER2 associated 
proteomic patterns from gastric cancer samples only to predict HER2 status in gastric 
cancer samples. We achieved a high accuracy for the SVM (91%; 95% confidence 
interval (CI-95%): ±0%), but both methods perform poorly as we obtained sensitivities 
of 0% (Table 2-5, A). This may be due to susceptibilities of the models to class 
distribution imbalances and the small number of samples in the training set. 
Next, we investigated the classificatory capability when proteomic data originating 
from one cancer type is employed for prediction in another cancer type. Here, spectral 
data from breast cancer was used to predict the HER2 status in all gastric cancer 
samples (Table 2-4, B). The SVM based classifier was able to detect 65% of the HER2 
positive patients (CI-95%: ±8%) while maintaining a high specificity of 92% (CI-95%: 
±2%; Table 2-5, B).  
Generation and testing of a universal HER2 classifier 
In an effort to generate and evaluate a universal HER2 classifier, the next training set 
combined the profiles of different cancer types. Therefore, non-breast cancer samples 
were added to the previous training set. The classification performance was assessed 
twice; first on a test set consisting just gastric cancer samples (Table 2-4, C), and 
secondly on a mix of breast and gastric cancer samples (Table 2-4, D). 
While there is no significant improvement in overall accuracy for the models in setting 
C, the Random Forest’s sensitivity benefitted significantly from the addition of the 
gastric cancer samples in the training set (from 28% to 50%; CI-95%: ±7%; p=0.004; 
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Table 2-5, C; Supplemental Table 2-3). Similarly, the sensitivity of the Support Vector 
Machine slightly increased to 73% (CI-95%: ±5%). 
Finally, in order to test the classifiers for universal classificatory power, also breast 
cancer patients were added to the test set (Table 2-4, D). Because of the high 
prevalence of breast cancer cases in the training set, all classifiers gain in sensitivity 
(p<0.05; Supplemental Table 2-3), even though with a little drawback in specificity 
(p<0.05; Supplemental Table 2-3). This finally results in sensitivities of 70% (CI-95%: 
±3%) and 78% (CI-95%: ±3%) for the Random Forest and SVM with specificities of 87% 
(CI-95%: ±2%) and 88% (CI-95%: ±1%), respectively (Table 2-5, D). 
Table 2-5 Classification results for training set – test set line-ups A–D 
Setting Random Forest Support Vector Machine 
  
Sensitivity Specificity Accuracy Sensitivity Specificity Accuracy 
A Mean 0% 40% 37% 0% 100% 91% 
 
CI-95% ±0% ±4% ±4% ±0% ±0% ±0% 
B Mean 28% 95% 89% 65% 92% 90% 
 
CI-95% ±9% ±0% ±1% ±8% ±2% ±1% 
C Mean 50% 93% 89% 73% 91% 89% 
 
CI-95% ±7% ±2% ±2% ±5% ±1% ±1% 
D Mean 70% 87% 84% 78% 88% 87% 
 
CI-95% ±3% ±2% ±2% ±3% ±1% ±1% 
Prediction performances of the two classification algorithms - Random Forest and Support Vector 
Machine - were evaluated according to their sensitivity, specificity, and accuracy within their 95% 
confidence intervals (CI) for each setting as described in Table 2-4. 
 
2.4.6 Discussion 
In breast cancers overexpression of HER2 is present in approximately 10%–34% of 
invasive breast cancers, and overexpression is known to be associated with a more 
aggressive biology of the tumor leading to a poor prognosis and response to 
chemotherapy [151]. Therefore, HER2 expression status is routinely evaluated for 
every patient with newly diagnosed primary breast cancer by two testing methods: 
immunohistochemical analysis and fluorescence in situ hybridization. Positively tested 
patients are eligible for treatment with trastuzumab, a monoclonal antibody directed 
to HER2, where breast cancer patients benefit from a higher survival rate [152, 153]. 
The efficacy of this therapy has led to investigate the role of HER2 expression in other 
cancer types, including gastric and gastroesophageal adenocarcinomas. 
69 
 
In gastric cancer about 20% of the patients also show overexpression of HER2, with an 
imbalance in occurrence which favors intestinal (~24%) versus diffuse type (~5%) 
tumors [37, 48]. Recent studies also indicate that HER2 may be of prognostic 
significance in gastric and esophageal cancers, where HER2 overexpression is 
associated with a poor survival [37]. Furthermore, anti-tumor activity of trastuzumab 
has been documented on gastric cancer cell lines [154-157] and xenograft models 
[158, 159]. On the basis of these results, clinical studies have started to explore the 
therapeutic effect of trastuzumab on HER2-positive gastric cancer patients. The 
extensive phase III ToGA trial provided the first evidence that targeting HER2 results in 
a demonstrable survival benefit for patients [33].  
Thus, based on the relevance of determining the HER2 status in breast cancers and 
gastric cancers with regard to the selection of trastuzumab, we hypothesized that the 
HER2 status of a cancer may constitute a unique molecular feature that results from a 
range of specific molecular alterations that are independent of the site of the tumor 
and that might be reflected at the proteome level. 
In order to test this hypothesis we used imaging mass spectrometry (IMS), which 
allows the development of proteome classifiers which can separate cancers of specific 
clinical and molecular characteristics [69, 72, 140]. IMS leads to the specific acquisition 
of proteomic profiles from histopathological interesting features like tumor cell 
populations through the direct analysis of thin tissue sections [137]. Because IMS 
combines the advantages of label-free mass spectrometry with histology, it has 
developed rapidly throughout the last years in profiling of diseased tissues [99, 138, 
139]. Recently, we reported that IMS may generate a proteomic signature which 
correlates with HER2 expression and could be used to accurately define HER2-positive 
from HER2-negative breast cancer tissues [53]. In continuative, not-published 
experiments, we also proved the separability of gastric cancer according to HER2 
status on cell lines (data not shown). 
Based on these findings and the importance of rapid detection and confirmation of 
drugable targets in these cancers, we hypothesized that a breast cancer derived 
proteomic algorithm could also be used in gastric adenocarcinomas in order to predict 
HER2 status. Prediction of HER2 status by IMS is thereby based on the detection of 
masses which reflect molecular alterations that underlie HER2 overexpression. 
We explored the quality of HER2 status prediction by two different classification 
algorithms on various training and test set combinations. In our first setting, classifiers 
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were trained on spectra derived from non-breast cancer in order to predict HER2 
status in gastric cancer patients. However, in line with other studies [37, 48, 157], we 
observed a very low frequency of HER2-positive gastric cancers. This leads to the 
assumption that the training set may not be representative and balanced enough to 
become sensitive for HER2 positivity. In this scenario none of the classifiers achieved a 
good classification performance.  
In an innovative approach we used the expression profiles of the fully balanced breast 
cancer set from Rauser et al. in order to predict HER2 status in non-breast cancers 
[53]. Interestingly, the classification models obtained sensitivities of 65% (SVM: 
AUC=0.8) and 50% (Random Forest: AUC=0.7) while keeping specificities over 90%. 
The reason for the increase might be two-fold. First, the capability of the two 
algorithms to generalize to situations not presented in the training sets (over-fitting 
robustness), in our case the classification of gastric cancer samples by a breast cancer 
trained model. Second, the emphasis of the training set on m/z species that better 
reflect HER2 status. This would support our main hypothesis. In the previous scenario 
the very same m/z species showed the same trend, but were overshadowed by signals 
that may be associated with some other unknown feature (Figure 2-6). 
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Figure 2-6 Proteomic profiles of breast and gastric cancer tissues. A classifier based solely on 
the low-number gastric cancer training set may be biased by signals that are not associated 
with HER2 status (e.g. signals: b, d). Employing the well-characterized breast cancer training set 
will strengthen those m/z species in the classification model that are known to be HER2 specific 
(signals: a, c). 
As a next step, spectral data of breast and non-breast cancer were combined in an aim 
to construct a universal HER2 classifier. The performance of this classifier was tested 
both on a non-breast cancer set (setting C) as well as on a mixed cancer set (breast 
and gastric cancer in setting D). 
The SVM showed a significantly higher accuracy in the last setting (D) than the 
Random Forest approach (p=0.025; Supplemental Table 2-1). This may be linked to the 
better fit of the SVM to the training data (p=0.003, see Supplemental Table 2-1). 
However, the Random Forest showed similar results at an AUC=0.7 (see Supplemental 
Table 2-1). Thus, together with other advantages, like little parameterization and 
internal feature selection, it is an attractive alternative to the SVM [160]. 
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In both settings C and D, the two classifiers benefit from this addition by obtaining 
high sensitivity values of up to 70% and 78% (D). Together with high values for 
specificity (87% and 88%), both models offer an accurate classification of mixed cancer 
groups for HER2 expression status. 
In summary, in our pre-clinical study we found that HER2 status of gastric cancer could 
be predicted accurately by protein patterns originated from breast cancer, yielding 
accuracies above 90% independent of the prediction method. Although these results 
must be validated in larger series and can only be regarded as proof of principle, our 
findings indicate that – based on a proteome based classifier – molecular 
characteristics of cancers can be identified that are independent of the site of the 
tumor and may, therefore, reflect unique molecular and genetic alterations that help 
to identify drugable targets across different cancer types. 
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2.4.7 Supplementary material 
Supplemental Table 2-1 
 
Supplemental Table 2-1 Comparison of classification performances between Random Forest 
(RF) and Support Vector Machine (SVM) 
Minimum 
AUC – 
setting 
                         Performance values (mean)              Comparison: RF vs. SVM 
Random Forest (RF) 
Support Vector Machine 
(SVM) P-values (Wilcoxon test) 
Sensitiv
ity 
Specific
ity 
Accura
cy 
Sensitiv
ity 
Specific
ity 
Accura
cy 
Sensitiv
ity 
Specific
ity 
Accura
cy 
0.7 – A 0.0 42.7 38.9 0.0 100.0 91.1 - 0.000 0.000 
B 50.0 95.1 91.1 77.5 40.0 43.3 0.020 0.010 0.000 
C 47.5 89.8 86.0 72.5 40.7 43.6 0.000 0.000 0.000 
D 69.0 86.0 83.3 86.0 44.7 51.3 0.000 0.000 0.000 
0.8 –  A 0.0 40.5 36.9 0.0 100.0 91.1 - 0.000 0.000 
B 27.5 95.1 89.1 65.0 92.2 89.8 0.000 0.001 0.150 
C 50.0 92.9 89.1 72.5 91.0 89.3 0.001 0.064 0.903 
D 70.0 86.6 84.0 78.0 88.3 86.7 0.002 0.318 0.025 
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Supplemental Table 2-2 
 
Supplemental Table 2-2 P-values (Wilcoxon U test) of statistical comparison of classification 
performances between 0.7 and 0.8 AUC thresholds 
Setting 
Accuracy Sensitivity Specificity 
RF SVM RF SVM RF SVM 
A 0.394 - - - 0.381 - 
B 0.027 0.001 0.004 0.046 0.676 0.035 
C 0.180 0.000 0.648 1.000 0.209 0.000 
D 0.606 0.000 0.648 0.010 0.753 0.000 
 
Supplemental Table 2-3 
 
Supplemental Table 2-3 P-values of statistical comparison (Wilcoxon U test) of classification 
performances between the settings A–D 
Minimum AUC 
Settings Accuracy Sensitivity Specificity 
to compare RF SVM RF SVM RF SVM 
0.7 A vs. B 0.000 0.000 0.000 0.001 0.000 0.000 
0.7 B vs. C 0.015 0.196 0.648 0.048 0.033 0.132 
0.7 C vs. D 0.196 0.167 0.000 0.002 0.209 0.380 
0.8 A vs. B 0.000 0.105 0.000 0.000 0.000 0.000 
0.8 B vs. C 0.714 0.556 0.004 0.167 0.049 0.164 
0.8 C vs. D 0.001 0.023 0.002 0.013 0.002 0.016 
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3 Conclusion and outlook 
 
The aim of my thesis was to search for molecular markers associated with clinically 
relevant questions such as prognosis or therapy prediction in patients with 
gastrointestinal cancers. In the results presented in this thesis, I showed protein 
expression profiles and single markers identified by MALDI imaging that are correlated 
with the overall survival and the HER2 expression status of gastric cancer patients. 
These marker profiles enable a stratification of patients with regard to survival and 
trastuzumab therapy selection which allows a more individual adaption of the 
treatment strategy. In comparison to other MALDI imaging studies, both published 
studies involved a large number of patient samples (181 for the survival study and 107 
for the HER2 study), thereby raising the confidence of the results. 
In the first study (section 2.3), a seven-protein signature was found to be correlated 
with the overall survival of intestinal-type gastric cancer patients, independently of 
major clinical parameters. Identification and immunohistochemical validation of three 
proteins confirmed their prognostic value for the stratification of existing clinical 
patient groups which might benefit from a different treatment. Future experiments 
for the functional characterization of the three proteins in gastric cancer cell lines have 
to evaluate their role in gastric cancer and their potential of new therapeutic targets. 
The protein identification rate, however, shows that one bottleneck in MALDI imaging 
is still the protein identification. New approaches are being developed that employ 
other mass analyzer technologies than TOF, such as Fourier transform based 
analyzers, together with alternative sample preparation protocols to achieve higher 
identification rates of m/z species [161, 162].  
Even though a protein can be identified, there is no guarantee that it can be measured 
and therefore validated by other techniques. This is especially true for combinatorial 
protein modifications that can easily be detected by mass spectrometry but hardly be 
discovered by other approaches [163]. Such modifications can harbor clinical relevant 
information, which has also been shown in the same study, where a peak belonging to 
a single acetylated histone H4 could also be correlated with a reduced survival of the 
63 gastric cancer patients (data was not included in publication). This modification, 
which is frequent on histones, belongs to the epigenetic effects which regulate gene-
expression through chromatin remodeling [164]. As a multitude of new epigenetic 
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drugs are being developed, one can imagine the application of MALDI imaging to 
directly measure both, the drug’s distribution, as well as the effects on its target 
molecules (“pharmacoproteomics”) [165]. 
In the second presented study (section 2.4), protein expression profiles from gastric 
and breast cancers were used for the classification of the HER2 status of tumors, 
which is important for therapy decision making. As the MALDI imaging approach is 
more specific and less sensitive than the standard HER2 testing procedures, one may 
speculate if the reported protein classifier may detect all responders compared to the 
standard HER2 testing procedures, which can result in false-positive rates of up to 20% 
[166]. However, this hypothesis has to be tested in subsequent studies with clinical 
response data available. Interestingly, the HER2 classifier appeared to be applicable 
across different adenocarcinoma types, including breast and gastric cancer, and even 
cancer of the gastro-esophageal junction (data not shown). This suggests that HER2 
overexpression might be based on common molecular events irrespective of the 
tumor type and that data obtained by MALDI imaging can be combined and compared 
across different cancers and studies. A subsequent project from a colleague extended 
this idea and combined the data from six tumor types in order to determine the 
primary tumor of metastatic tumors [85]. 
It is of importance that the determination of HER2 status has been carried out on the 
mean spectra over cancer regions, i.e. the spatial distribution within data sets was not 
considered. However, this might be problematic in cases where HER2 positive cells 
constitute a minority and thus signals indicating HER2 positivity may be lost in the 
average spectrum [167]. To address this problem, a supervised, pixel-based 
classification of the HER2 status of breast cancers sections was carried out in 
consecutive experiments. This approach facilitated to identify samples with 
heterogeneous HER2 expression. This could be important because intratumoral 
heterogeneity has been identified as a major factor to influence prognosis and therapy 
response of patients [168, 169]. In this context, a high spatial resolution is required in 
order detect even smallest but relevant tissue cell populations.  
An increased spatial resolution could also have extended my studies to diffuse-type 
gastric cancers. These were mostly excluded from my studies because diffuse-type 
gastric cancer is characterized by a non-adhesive growth leading to the wide-spread 
distribution of single cancer cells in a tissue which makes their measurement without 
single cell resolution difficult. Several groups have worked on sample preparation 
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procedures and instrumentation to achieve now measurements at cellular and even 
sub-cellular level [170, 171]. 
Another important practical obstacle in imaging mass spectrometry is still the 
quantification of the signals measured. Solving this issue could facilitate inter-
laboratory comparability and reproducibility, opening possibilities for multicenter 
studies and, therefore, the clinical applicability of MALDI imaging. This has been 
recognized by the MALDI imaging community and is therefore in the focus of recent 
investigations [172]. Although both of my studies included an independent validation 
step, such harmonization would facilitate to test the general applicability of both 
protein signatures in larger multicenter cohorts, also prospectively. If my data are 
confirmed in larger numbers of patients, tissue-based proteomics profiling by MALDI 
imaging could have implications for the clinical management of patients with gastric 
cancer. 
In that way, one could envision the translation of MALDI imaging into clinico-
pathological routine. Especially in gastroenterology, which is significantly based on 
bioptic diagnostics, tissue samples from patients could be tested by MALDI imaging for 
the protein signatures found in my studies (Figure 3-1). This could assist the clinician in 
the clinical management of the patients with regard to therapy decision making and 
survival prediction – thus, making one more step towards a more personalized 
medicine. 
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Figure 3-1 Visionary application of MALDI imaging in a clinical setting (gastroenterology). 
MALDI imaging is able to analyze even smallest tissue samples from patients, such as 
endoscopic biopsies, which are routinely collected in a gastroenterological setting. The 
subsequent MALDI imaging analysis is quick, histology-directed and allows extracting spatially 
resolved, cell type-specific molecular signatures from a wide variety of molecule classes. These 
patterns may, therefore, objectively support the clinician or pathologist in relevant questions 
such as in tissue diagnostics, therapy response prediction, or disease outcome prediction. 
Taken from [77]. 
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4.1 MALDI imaging mass spectrometry 
In the following subsections the basics, the advantages and limitations of mass 
spectrometry will be briefly explained with regard to the relevant issues for MALDI 
imaging. Then, more details will be given on the principle, the workflow and the 
applications of MALDI imaging. 
 
4.1.1 Mass spectrometry 
Mass spectrometry refers to a methodology that ionizes sample molecules and 
separates the ions according to their mass-to-charge (m/z) ratio in high vacuum. The 
result, a mass spectrum, is a graphical plot of measured ion intensity versus its m/z 
value (example: Figure 4-3, B and C) [60]. 
Components of a mass spectrometer 
A mass spectrometer device consists of three major parts: an ion source, where the 
analytes are ionized, a mass analyzer which separates the ions according to their m/z 
ratio, and a detector which records the ion current (Figure 4-1) [173].  
 
Figure 4-1 Principal components of a mass spectrometer. A mass spectrometer device consists 
of an ion source, where the analytes are ionized, a mass analyzer which separates the ions 
according to their m/z ratio, and a detector which records the ion current. The system must be 
under vacuum condition for the unhindered analysis of the analytes. A data analysis system for 
the interpretation of the recorded data is also a basic component. 
There are several techniques for the ionization of an analyte. These can be grouped 
into four basic categories: electron, spray, desorption, and chemical ionization 
techniques [174]. Electron and chemical ionization are suitable for small, volatile 
compounds. In contrast, “soft” ionization techniques like the electrospray ionization 
(ESI) and matrix-assisted laser desorption ionization (MALDI) samples allow measuring 
large labile molecules such as proteins. While ESI ionizes molecules within liquid 
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samples, MALDI is applied for ionization of molecules embedded into a solid matrix 
[173]. Both methods have been crucial for the rapid advance in proteomics [60]. With 
regard to mass spectrometry as an imaging technique, the ionization must be done 
from a solid surface, leaving the desorption methods, such as MALDI, as the only 
choice [174]. 
Matrix-assisted laser desorption/ionization (MALDI) 
Preparation for MALDI experiments requires the sample to be mixed with a low 
molecular weight organic molecule, called ‘matrix’. This matrix has to show high 
energy absorption at the wavelength of the applied laser beam. In addition, each type 
of matrix favors the ionization/desorption of a different type of biomolecules (Table 
4-1) [173]. The most common matrix compounds in proteomic experiments are 2,5-
dihydroxybenzoic acid (DHB), α-cyano-4-hydroxycinnamic acid (CHCA), and sinapinic 
acid (SA) [175]. These compounds are usually dissolved in a 50%–70% acidified organic 
solvent solution which promotes analyte extraction [175]. 
Table 4-1 Common matrices. Taken from [173] 
Analyte Matrix 
Peptides 2,5-Dihydroxybenzoic acid (DHB, gentisic acid) 
 
alpha-Cyano-4-hydroxycinnamic acid (CHCA) 
 
3-Hydroxypicolinic acid (3-HPA) 
 
2,4-Dinitrophenylhydrazine (2,4-DNPH) 
Proteins 2,5-Dihydroxybenzoic acid (DHB, gentisic acid) 
 
alpha-Cyano-4-hydroxycinnamic acid (CHCA) 
 
3,5-Dimethoxy-4-hydroxycinnamic acid (SA, sinapinic acid) 
Oligonucleotides 4,6-Trihydroxyacetophenone (THAP) 
 
3-Hydroxypicolinic acid (3-HPA) 
Lipids 2,5-Dihydroxybenzoic acid (DHB, gentisic acid) 
  2,6-Dihydroxyacetophenone (DHA) 
 
After evaporation of the solvent, analyte molecules are embedded into the crystal grid 
of the matrix (Figure 4-2). Under high vacuum conditions, a pulsed laser beam is 
directed toward the co-crystal. Matrix molecules are excited by the laser energy which 
results in an explosion and transition of matrix and embedded sample analytes into 
the gas phase. During this process ionization of the analyte molecules (M) takes place 
which typically results in single protonation (M+H)
+
 or deprotonation (M-H)
-
; addition 
of a single sodium (M+Na)
+
 or potassium atom (M+K)
+
 is less frequent.  
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Figure 4-2 Principle of matrix-assisted laser desorption/ionization (MALDI). Analytes are co-
crystallized with a light absorbing matrix. A short laser pulse irradiates the matrix surface. The 
matrix absorbs the energy which leads to a desorption process of both matrix and analyte 
molecules. During this process analytes are ionized by protonation which facilitates the 
acceleration of the produced ions by an electrostatic field towards the mass analyzer. Modified 
from [173]. 
MALDI is referred to as “soft” ionization method as most of the energy is absorbed by 
the matrix, leading to less fragmentation of the analyte components. This makes 
MALDI especially suitable for the ionization for larger biomolecules such as peptides or 
proteins which in turn makes it attractive for proteomics research. 
Mass analyzers 
Once the ions have been created they have to be separated in a second step by the 
mass analyzer. This can be done according to the needs of the scientist on the basis of 
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different physical principles. There are plenty of different mass analyzer techniques 
including quadrupole, ion trap, time-of-flight (TOF), Fourier-transform ion cyclotron 
resonance (FT-ICR), or Orbitrap mass analyzers. For a concise overview and 
comparison of these technologies please refer to the literature [67, 174]. Most 
commercial MALDI based mass spectrometers are combined with a time-of-flight 
(TOF) separator.  
Time-of-flight mass analyzer 
Briefly, in the time-of-flight (TOF) approach, the m/z value of a molecule is determined 
by measuring its flight time through a drift tube under high vacuum (Figure 4-3) [11]. 
 
Figure 4-3 Time-of-flight (TOF) separation of MALDI ions. Following acceleration in the MALDI 
ion source, the ions can be separated according to their different times of flight trough a 
vacuum tube which depend on their mass and charge (m/z) (A). The intensities measured by 
the detector depend on the number of ions with the same m/z. A typical mass spectrum in the 
84 
 
mass range between m/z 2,000 and 20,000 is shown in (B), with a magnification of the mass 
range between m/z 5,000 and 8,000 (C). Taken from [11]. 
Directly after the molecules having been ionized they undergo, still in the ion source 
device, acceleration in an electrostatic field (Figure 4-2). At the end of the acceleration 
path, all molecules, even of different masses, have gained the same potential energy. 
This corresponds to the amount of kinetic energy that the molecules dispose to 
traverse the subsequent linear field-free drift region:  
                
 
      
  
Formula 1 Energy for traversing TOF drift tube. Abbreviations: z, charge number of the particle; 
e, elementary charge; U, the electric potential for acceleration; m, mass of the particle; v, 
resulting velocity of the particle at the end of acceleration. Taken from [173]. 
The final velocity of a molecule through the flight tube is, thus, determined by its mass 
and charge. Obviously, heavier molecules will be slower than lighter molecules (Figure 
4-3, A). Given a known length for the flight tube, the time to traverse the tube is:  
      
Formula 2 Time for traversing TOF drift tube. Abbreviations: t, time for traversing the TOF drift 
tube; L, length of drift tube; v, velocity of particle. Taken from [173]. 
By measuring the time from laser pulse till ion hit at the detector, the m/z ratio of a 
molecule can be calculated by combining the two previous equations:  
 
 
 
          
  
 
Formula 3 Calculation of mass to charge ratio. Abbreviations: m/z, mass to charge ratio; e, 
elementary charge; U, the electric potential for acceleration; t, time to traverse drift tube; L, 
length of the drift tube. Taken from [173]. 
An important property of a mass analyzer is the mass resolution. The resolution in 
mass spectrometry is the ability to distinguish two peaks with similar mass-to-charge 
ratios [173]. There are effects that reduce the resolution. Molecules of the same mass 
may have an initial kinetic energy spread which may be caused by differences in place 
and time of ionization or differences in amount and direction of initial velocities [176]. 
The introduction of a reflector may correct these differences, thus yielding higher 
mass resolutions [176]. 
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The reflector is made of an electrostatic field that deflects the ion beam at the end of 
the flight tube toward a second detector (Figure 4-4). The depth of penetration into 
the electrostatic field depends on the kinetic energy of the ions; the more energy, the 
deeper the penetration and the longer the total way to reach the final detector. Thus, 
differences in initial energies of equal masses can be corrected by depth of 
penetration into the reflector. However, this is only true for lower m/z values. At 
higher m/z the reflector fails to achieve significant higher resolutions [176]. 
 
Figure 4-4 Principle of TOF based mass spectrometer with reflector. The reflector consists of an 
electrostatic field that deflects the ion beam at the end of the flight tube toward a second 
detector. The depth of penetration into the electrostatic field corrects differences in initial 
energies of equal masses, thus increases the resolution power of the mass spectrometer, 
however only for molecules up to 6kDa. For detection of higher molecular weight molecules 
the electrostatic field of the reflector is disabled and the linear detector is activated. Taken 
from [175]. 
Tandem mass spectrometry 
The reflector is also used to separate fragments of molecules that occur in the area of 
the first drift region. This phenomenon is called post-source-decay (PSD). PSD ions 
cannot be separated by a linear TOF mass analyzer as they have the same kinetic 
energy but different masses. However, the analysis of the PSD fragments delivers 
useful information concerning the structure and identity of the original ion. 
The measurement of PSD fragments of a specific parent ion may be realized by two 
consecutively arranged TOF mass analyzers (TOF/TOF, a.k.a. MS/MS, or tandem MS). 
The first TOF section acts as precursor m/z selector by deflecting other ions than of 
interest. The fragmented ions are then separated and detected by the second TOF 
[177]. Optionally, the precursor ion may be also artificially dissociated by collision gas 
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in an intermediate region, before being transmitted to the second TOF component 
[176]. 
Tandem MS has become one of the major tools for biomolecule analysis in the mass 
range m/z 500– 3,000 [176]. In proteomics, proteins are moved to the MS/MS mass 
range by performing a proteolytic digest, so that the resulting peptides of the proteins 
are actually analyzed. 
Abilities of MALDI-TOF mass spectrometry for proteomics research 
MALDI-TOF based mass spectrometry has become an indispensable tool in proteomics 
research. This is mainly due to its abilities listed below:  
 Soft ionization by MALDI enables measurement of intact large biomolecules 
such as oligonucleotides, peptides, and proteins. 
 Rapid, label-free and simultaneous (multiplexing) acquisition of hundreds to 
thousands of mass signals. 
 Measurement of post-translational modifications (PTM) such as 
phosphorylation, acetylation and methylation, as PTMs alter the mass of a 
protein in a predictable fashion [60]. 
 High sensitivity (down to femtomoles) which allows even small amounts of 
sample volumes to be analyzed [67]. 
 Mass range, which reaches from small (100 Da) to large molecules (>300 
kDa), allowing measurement of small molecules, metabolites, lipids, 
peptides and proteins [175]. 
 Determination of the identity or structure of molecules by analysis of their 
PSD fragments 
Besides these powerful abilities, MALDI-TOF also suffers from several disadvantages: 
 No direct knowledge of molecular identity, but “only” m/z values 
 PSD-based identification best possible on pre-purified (by gel or liquid 
chromatography) small peptides (<4,000 Da) or digested proteins 
 Mass resolution and accuracy drops with higher mass range 
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4.1.2 MALDI imaging mass spectrometry 
MALDI imaging mass spectrometry has been developed in the late 1990s with the idea 
to extend the application of conventional MALDI-TOF experiments to tissue sections to 
incorporate histological information [137]. During an MALDI imaging experiment a 
mass spectrum is acquired for each measuring spot, a so called pixel, in a predefined 
raster across a sample tissue section, resulting in a two dimensional distribution map 
for each measured m/z value (Figure 1-11) [68]. Importantly, as the sample is not 
damaged during the measurements, the very same tissue section can be stained 
conventionally afterwards, digitally scanned, and directly co-registered to the mass 
spectrometric data. This allows studying the spatial distribution of mass signals, 
corresponding to proteins, within their histological context. Furthermore, protein 
signatures can be specifically allocated to certain cell-type, such as tumor cells, 
inflammatory cells, connective tissue, etc. 
MALDI imaging was not the first mass spectrometry based imaging method. Secondary 
ion mass spectrometry (SIMS), introduced in the 1960s, uses an ion beam of high-
energy particles to cause, upon impact onto a sample surface, the emission of 
secondary ions that are then analyzed in a mass analyzer. SIMS instruments achieve 
nanometer size pixels but are usually limited in their mass range to below 1,000 Da 
[178]. 
In contrast to SIMS, MALDI allows investigating higher molecular weight content of 
tissues, such as proteins, peptides, lipids in their histomorphological context, however 
at a lower lateral resolution with typical pixel sizes of 20 to 200 µm available on 
commercial systems [68]. 
Until now, MALDI imaging of tissues is mostly done on cryo-preserved tissues. 
Nevertheless, new protocols are in development which enable the application to 
formalin-fixed, paraffin-embedded (FFPE) or alcohol preserved tissues [179-182]. In 
the next paragraph, the workflow of a typical MALDI imaging experiment is described 
for the well-established analysis of frozen tissues, which has been used in this thesis to 
analyze proteins. 
Sample preparation 
The whole workflow is depicted schematically in Figure 4-5. 
As first step, a native tissue section is placed by cryo-sectioning onto a pre-chilled and 
conductive glass slide. The conductive glass slide, typically realized by indium-tin-oxide 
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coating, facilitates mass spectrometry experiments and histological analysis to be 
done on the very same section. In our studies, slides were previously coated with poly-
L-lysine for better tissue adherence. The samples are then briefly rinsed in an 
increasing alcohol solution series to remove salts and fixate the tissue.  
As in any other MALDI experiment, samples have to be covered with a crystalline 
matrix before mass spectrometry can be performed. The analytes are extracted by the 
solvent in the matrix solution and incorporated into the matrix crystal structure after 
evaporation of the solvent. In direct tissue analysis by MALDI imaging, organic matrix 
solution is placed over the entire tissue section. The matrix deposition needs to be 
homogeneous and reproducible in order to guarantee comparability within and 
between measurements. The matrix can be applied either manually, by robotic 
spotting, nebulization, or sublimation, before laser shots are subsequently performed 
across the tissue sample. Systematic multi-measurement studies should use 
automated devices to guarantee the comparability of different measurements. An 
overview of different matrix application techniques can be found elsewhere [68, 175]. 
 
Figure 4-5 MALDI imaging mass spectrometry workflow. Before measurement a tissue section 
is cut and mounted onto a conductive glass slide and covered by a MALDI compatible matrix, 
which forms analyte-matrix co-crystals (top panel). MALDI mass spectrometry experiments are 
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repeated for all measurement spots on the tissue section (middle panel). The distance between 
the measurement spots defines the spatial resolution (=pixel size) of the resulting MALDI 
image. The intact tissue section can be stained and superimposed to the spatially resolved 
mass spectrometric data. This allows on the one hand visualizing mass signals for correlation 
with the underlying tissue morphology (lower panel, right). On the other hand, cell-type 
specific expression profiles can be obtained from regions of interest within the tissue (lower 
panel, left). Taken from [183]. 
Sample measurement 
After introducing the sample slide into the mass spectrometer, measurement regions 
are defined, which are then analyzed within a user-defined lateral resolution which is 
typically between 20 μm and 200 μm on commercial instrumentation [184]. An even 
higher lateral resolution could be achieved by Chaurand et al. using a custom-built 
mass spectrometer. They were able to perform MALDI imaging measurements of 
phospholipids at a cellular level, reaching resolutions lower than 5 µm [170]. 
The lateral resolution, i.e. the distance between the measurement spot, is limited both 
by the laser focus size as well as the average size of the matrix crystals [185]. 
Automated spotting devices have the advantage to apply small droplets of matrix or 
enzymatic solutions in a precise, uniform and highly reproducible manner. However, 
the droplet size (≥150 μm) determines the maximum lateral resolution. Automated 
spray coaters, like the ImagePrep station (Bruker Daltonik, Bremen, Germany) achieve 
smaller droplet sizes (~20 μm), thus facilitating higher resolution measurements [175]. 
The sample may be analyzed in linear or reflector mode depending on the type of 
analytes and the corresponding m/z range which varies between the different 
matrices. Mass ranges for proteins are usually between 2,000 and 30,000 Da, for 
peptides between 600 and 4,000 Da, and for small molecules between 100 and 800 
Da. 
Co-registration of stained sample 
One of the great advantages of MALDI imaging is that the tissue sample is not 
destroyed during the measurement. This allows for the precise correlation of mass 
spectrometric imaging data with the morphological features of the very same tissue 
section, as a consecutive section may differ in morphological details. For this, the 
matrix is eluted after the measurement by washing the sample with an alcohol 
solution before staining it with hematoxylin and eosin (H&E) [103]. The slide is then 
scanned with a digital slide-scanner and co-registered to the mass spectrometric data.  
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Data processing and analysis 
After co-registration, the spatial distribution of all m/z values can be assessed within 
the histomorphological features of the tissue (Figure 1-11). 
For clinical studies, the analysis pipeline is usually to extract the mass spectrometric 
data from histological interesting regions with designated states (e.g. healthy tissue, 
tumor tissue, or responder patient). Next, these data usually undergo normalization, 
recalibration (both to enable comparability between measurements), and peak 
picking. After processing, the peaks intensities (=mass signals representing molecules) 
of these spectra are tested for correlation with given biological or clinical endpoints. 
The spectra may also be clustered to investigate the molecular composition of a tissue 
sample without prior knowledge (more details can be found in the chapter 4.2 on 
statistical methods in MALDI imaging). 
Protein identification 
While MALDI imaging allows measuring hundreds of masses at once, it has the 
problem that only the molecular weight of molecules is reported without any name 
associated to them. This makes an additional protein identification step necessary. 
Protocols to identify the names corresponding to the masses are neither standardized 
nor universally applicable. These approaches can be grouped according to their site of 
measurement, on-tissue or extract based, and the application of digest, top-down 
versus bottom-up (Figure 4-6) [98]. 
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Figure 4-6 Workflow of protein identification. Depending on the molecular weight of the 
molecule of interest, either top-down or bottom-up identification has to be performed. For 
smaller molecules (<3.5kDa), a direct ionization and gas phase fragmentation (MS/MS) of the 
protein of interest inside the mass spectrometer can be performed (top-down), whereas the 
analysis of larger molecules involves protease digestion of the protein (bottom-up), usually 
within a mixture of other proteolytic fragments. Thus, additional separation steps by liquid 
chromatography (LC) or gel electrophoresis are necessary. Taken from [98]. 
In the top-down approach, no digestion is performed so that the full protein is 
fragmented and the resulting ions are used for identification. The advantage of the 
top-down approach is that the resulting identity can be directly matched to the mass 
obtained from MALDI imaging.  On-tissue (in situ) identifications are only possible for 
low mass proteins and peptides (<3,500 Da) [186]. Larger proteins cannot be identified 
by top-down on-tissue and have to be first extracted and isolated by gel or liquid 
chromatography steps. The isolation process of tissue extracts, however, is tedious 
and complicated. 
Identifications involving digestion of proteins is called bottom-up identification. The 
bottom-up analysis of tissue extracts provides long lists of identities. However, they 
are difficult to match to the unknown masses from undigested MALDI imaging 
experiments. Successful on-tissue identifications have been achieved in analyzing FFPE 
or frozen tissue sections which underwent previous digestion process. This generated 
hundreds of tryptic peptides in a mass range (m/z 500-3,000) amenable for sequence 
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analysis directly from their location in the tissue [179, 187, 188]. However, with a 
digest the information about the full protein is lost (isoforms, possible modifications 
on the undetected fragments, etc.). 
Taken together, there are examples of successful identifications, either with or 
without application of digest, but a standardized protocol is not available yet. 
Advantages and limitations of MALDI imaging mass spectrometry 
Despite the limitation of not providing directly the identity for each m/z value, MALDI 
imaging constitutes a powerful discovery tool for clinical research in the field of 
proteomics, lipidomics and pharmacokinetics, which has its strengths and limitations 
[98, 99, 133, 189]. 
 Advantages: analysis of smallest sample amounts (biopsies); histology-driven 
analysis;  
label-free; multiplexing; full protein analysis (PTMs); avoids time-consuming 
extraction, purification or separation steps, which have the potential for 
producing artifacts; application to FFPE/frozen tissue micro arrays; high 
throughput 
 Limitations: no direct protein identification; potential ion suppression; 
restricted to low molecular weight (<30 kDa) and soluble proteins 
 
4.1.3 Road map to clinical-relevant markers by MALDI imaging studies 
As shown, MALDI imaging is a powerful proteomic screening tool that may constitute 
the first step for providing specific marker candidates. However, as MALDI imaging 
detects “only” masses, subsequent protein identification approaches have to provide 
the molecular identity of the mass of interest. 
The knowledge of the molecular identity facilitates the validation of the significance of 
the candidate marker. A validation, especially in proteomics or transcriptomics 
studies, by a large number of independent patients is considered of great importance, 
as lots of previously proposed markers have shown not to be reproducible [64, 90, 
190]. For example, a meta-analysis of the most prominent cancer studies using 
expression profiling showed that in five studies the original results could not be 
reproduced [191]. The fact that until 2004 in only 10% of microarray studies an 
independent validation has been performed may explain why only few markers have 
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so far reached the phase of clinical trials or even the integration into clinical practice 
[54, 190]. In this context and for an initial intra-study validation, Meyer et al. favor 
immunohistochemistry using tissue microarrays, as they allow a parallel analysis of 
multiple tissue specimens for statistical validation under marginal methodical 
variances [64].  
In consequence, the validation of a marker candidate by immunohistochemistry on 
tissue microarrays of independent patient cohorts has been incorporated into most 
marker discovery workflows (Figure 4-7) [68]. To exclude subjective observer 
evaluation of staining, objective image evaluation may be performed by digital image 
analysis software.  
 
Figure 4-7 MALDI imaging mass spectrometry based biomarker identification workflow. As an 
unlabeled, multiplexing, morphology-driven approach, MALDI imaging is a powerful method 
for the discovery of protein signals as candidate biomarkers for a given clinical end point. After 
protein analytic identification of a candidate signal, the protein should be validated in an 
independent patient cohort by a different technique such as immunohistochemistry before 
being considered as a reliable tissue biomarker candidate. Taken from [68]. 
In addition, if a tissue marker has proven reliability in the validation cohort, it may be 
considered to check its applicability to serum. In contrast to direct serum studies, the 
depicted road map bypasses the sensitivity problem of traditional serum biomarker 
discovery, which is due to the dynamic range of the serum proteome, by delivering a 
target molecule from the possible origin of the disease [55]. 
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4.2 Statistical methods and considerations in 
MALDI imaging studies 
MALDI imaging analyses result in high-dimensional data sets consisting of several 
thousand of spatially resolved mass spectra, each of which contains hundreds or 
thousands of mass signals [192]. Such data sets are known to suffer the ‘curse of 
dimensionality’ [193]. 
As a consequence, advanced statistical data mining methods are required which take 
into account the nature of MALDI imaging data. Several of these techniques have been 
imported from the gene expression analysis community, which faces similar problems 
[68]. 
With regard to the presented thesis here, deeper explanations will be given on the 
methods applied in these studies. However, it is also intended to provide a general 
overview on the most important aspects of data mining and methods applied in 
MALDI imaging. 
 
4.2.1 Marker discovery/feature selection 
For studies with clinical questions, the first step in the MALDI imaging data analysis 
pipeline is to extract the mass spectrometric data from histological interesting regions 
with designated states (e.g. healthy, tumor, HER2 positive or poor survivor). After 
extraction of the corresponding spectra and subsequent spectra processing, the mass 
signals (features) of these spectra can be tested for correlation with given biological or 
clinical end points.  
Statistical tests 
These tests are performed by classical statistical tests like the Mann-Whitney U test, t 
test, Fisher test, Pearson’s correlation, or the log rank test for survival analysis. 
However, due to the curse of dimensionality, there is a risk of identifying false-positive 
features, as the type I error (error for false-positive discovery) has to be multiplied by 
the number of features that are tested. For instance, by setting the significance level 
of type I error to α=0.05, and testing 100 features, there will be 5 potential type I 
errors, i.e. 5 signals that are expected to be significant by mistake [193]. This multiple-
testing error can be corrected by p-value adjustment procedures like the ones from 
Bonferroni or Benjamini-Hochberg [194]. If not stated otherwise, reported p-values of 
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m/z species in the studies presented here were adjusted by Benjamini-Hochberg 
correction. 
Other techniques to control for the false discovery rate have already been employed 
in the field of MALDI imaging like the permutation t-test [79] or the weighted ﬂexible 
compound covariate method [70]. Similar to the permutation t-test, the widely used 
significance analysis of microarrays (SAM) uses repeated permutations of the data to 
determine if a feature is significantly related to a clinical endpoint [71]. 
Another critical issue is the study size. To improve statistical reliability in preclinical 
MALDI imaging research studies, a minimum number of 50–60 samples have been 
proposed [189]. In both studies conducted for this thesis, the number of involved 
sample surpasses this recommended minimum number: for the study on prognostic 
proteins 63 patient samples have been measured and the HER2 classification study 
involves 107 samples. 
Other selection criteria 
In terms of applicable biomarkers, high values for sensitivity and specificity are of 
importance. A high discriminatory power may be indicated by the significance of a 
statistical test. However, the mutual relationship between sensitivity and specificity is 
best represented graphically by a receiver operating characteristic (ROC) curve (Figure 
4-8). The true positive rate is plotted versus the false positive rate for a varying cut-off. 
The resulting area under the curve (AUC) is an indication for the discriminatory power 
of the marker [41]. The AUC ranges from 0.5 for a total random classification to 1.00 
for a perfect classification, where both sensitivity and specificity have values of 100%. 
 
Figure 4-8 Receiver operating characteristic (ROC) curve. The ROC curve (right panel) is a 
graphical representation of the mutual relationship between sensitivity (true positive rate) and 
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specificity (1 - false positive rate) by varying a cut-off for the separation of two groups (red and 
blue, left panel). The discriminatory power may be represented by the area under the ROC 
curve (AUC), where the area 1 represents maximum discriminatory power and 0.5 is equal to a 
random classification (red dashed curve in the right graph). Taken from [41]. 
Other techniques alter the original representation of the variables by projection 
(principal components analysis) or compression using information theory [195]. The 
principal components analysis (PCA) is mostly used to reduce the number of variables 
to so called principal components while maintaining most of the information.  
In my presented studies, SAM and ROC analyses have been used to identify relevant 
features in terms of prognostic significance and discriminatory power between HER2 
positive and negative samples, respectively. 
 
4.2.2 Classification algorithms 
Classification algorithms are used to group objects according to their differences or 
similarities in a defined feature space. For MALDI imaging data sets, usual objects to 
classify may be single spectra of a tissue section or a representative spectrum taken 
from a region of a sample (e.g. tumor areas). The mentioned feature space can be 
based on all mass signals detected or on a signature of relevant mass signals which 
may had been determined previously by a feature selection process, as explained 
before. 
Two types of classification algorithms can be distinguished: unsupervised or 
supervised. Unsupervised methods can be applied to the objects without prior 
knowledge, making it a discovery tool for identifying molecularly similar groups of 
objects, termed ‘clustering’. In contrast, supervised methods rely on a previous 
training of the classification model by samples with known status (e.g. responder, poor 
survivor). Thus, depending on the combination of classification algorithm and objects 
to classify, different scientific questions can be addressed in MALDI imaging studies 
(Table 4-2). 
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Table 4-2 Types and application of classification algorithms in MALDI imaging 
Classification of spectra … Statistical classification method 
  Unsupervised Supervised 
Within one sample for … 
Investigation of molecular 
composition within one sample 
(e.g. to study tumor heterogeneity) 
by clustering algorithms 
[88] 
Spatially-resolved classification of 
tissue regions (e.g. HER2 status, 
potential metastatic cells) 
[76] 
Between samples for … 
Ad hoc clustering of 
samples/patients with known or 
unknown status into different 
groups (e.g. for discovery of 
cancer subtypes) 
[196] 
Predictive classification of 
samples with unknown status 
after training of the classifier with 
samples of known status (e.g. 
responder, poor survivor) 
[72] 
 
The most important aspects to consider when choosing a certain algorithm are the 
degree of parameterization of the method and its susceptibility to overfit i.e. not being 
able to reproduce the results in another sample set. Both are closely connected. As 
results are prone to vary with increased freedom of parameterization, reproducibility 
is assured by employing algorithms with a very low number of parameters. 
In the following paragraphs, several of the most commonly employed classification 
methods are introduced; however, the focus will be on methods used in this thesis.  
Hierarchical clustering (Unsupervised clustering) 
Unsupervised algorithms group objects according to their distance in a given feature 
space which is defined in MALDI imaging by the selected m/z species. One of the most 
popular unsupervised methods is the hierarchical clustering. The peculiarity of 
hierarchical clustering is that it organizes the single objects and clusters according to 
their similarities in a tree-like structure called dendrogram (see Figure 1-8, B). Clusters, 
represented by nodes in the tree, are built by iteratively grouping single objects or 
clusters according to a defined distance metric until all objects are located in the same 
cluster (root of the tree). 
The advantage of this procedure is that it does not require prior knowledge about the 
number of expected clusters as it finds a whole cluster hierarchy. Disadvantages are 
the memory consumption during calculation and the parameterization, which are the 
distance metric and linkage method.  
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However, this method has extensively been employed in gene-expression analyses 
where profiles have been used to discover new cancer subtypes or to predict survival 
[197, 198]. 
In MALDI imaging, this method has been used by Deininger et al. to assess molecular 
heterogeneities within morphological identical entities of gastric cancer tissue sections 
[88]. Another work by Yanagisawa et al., could distinguish subgroups of non-small-cell 
lung cancer with different disease outcome on basis of clustering MALDI profiles [69]. 
Other unsupervised algorithms 
Similarly, there are also non-tree based clustering algorithms. Importantly, the 
number of expected clusters has to be defined in advance.  
Some of them have been employed to perform spatial segmentation on MALDI 
imaging data sets [199]. Alexandrov et al., for example, used high dimensional 
discriminant clustering (HDDC) to group MALDI imaging spectra whereas the number 
of groups was defined beforehand according to the morphological entities observed in 
the sections [200]. Subsequent super-resolution segmentation was applied to 
artificially increase the resolution of the images for better interpretation [201]. 
Decision tree (Supervised classification) 
Supervised methods, in contrast, make use of additional information that comes with 
the initial data to construct a classifier. This model may then be used to predict the 
unknown status of other data.  
A very intuitive representation of a supervised algorithm is the decision tree. As the 
name says, decisions are organized in a tree where each node represents a decision 
according to a certain feature. For classification of a test object, it has to make its way 
from the root node to one of the leaves which represent the final assignment. An 
example is given as tree 1 from Figure 4-9. As depicted, the decisions of the tree 
define regions in an n-dimensional space where n is the number of involved features.  
The construction of the tree is an iterative process which starts at the root node. At 
each step the optimal feature for division of the remaining objects is selected. The 
process stops at perfect separation of objects or in case no divisive feature is left. 
Main advantage of this method is the easy interpretability of the tree by humans. That 
is why it is commonly used e.g. in medicine for diagnostic or treatment guidelines. 
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Disadvantage is its susceptibility for overfitting, i.e. the lack of generalization capability 
which is recognizable at the strict decision boundaries of tree 1 in Figure 4-9 which are 
localized very closely to the objects. 
Random Forest 
Random Forest can be described as a collection of decision trees with controlled 
variation (Figure 4-9). In contrast to single decision trees, the algorithm is robust to 
overfitting, while yielding high prediction accuracy [145, 202]. It is capable of dealing 
with a large number of input variables, and performance is robust with respect to 
parameterization [145]. 
Overfitting is avoided by introducing several random elements during the learning 
phase of the forest. These include random sample selection for construction of each 
new tree and random feature selection for samples splitting at each node. Thus, the 
major parameters for training are the numbers of trees and features randomly chosen 
at a node [145].  
For classification of a test sample, each tree of the forest is evaluated individually. The 
class label with the highest number in votes is assigned to the test sample. 
In MALDI imaging, Hanselmann et al. have provided evidence that the Random Forest 
classifier can be used for accurate, automated in situ annotation of tissues [145]. 
 
Figure 4-9 The Random Forest classification algorithm. A Random Forest classifier is a collection 
of decision trees where the single trees are constructed from bootstrap samples. Two trees of 
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the forest are shown in detail (left and center panels): at each node, the feature which allows 
for the best class separation is chosen (with respect to the subset of features selected for that 
node). The corresponding partitioning of the objects in the feature space is shown below with 
the decision boundary plotted in purple. On the very right, the decision boundary of the 
combined Random Forest is displayed which is based on the majority vote of the individual 
trees. Taken from [145]. 
Support Vector Machine 
The Support Vector Machine (SVM) is a powerful classifier which has been extensively 
used in a variety of high-dimensional classification problems in biomedicine, amongst 
others also for proteomic data sets [142, 143, 146]. 
Learning of a SVM involves the finding of an optimal hyperplane in the feature space. 
The optimal hyperplane is defined as having the maximum distance from the objects 
of the different classes (Figure 4-10) [193]. The support vectors, which are 
perpendicular to the hyperplane help to find the optimal hyperplane, as they define 
the distance between the objects and the separating plane. This maximum margin 
method guarantees generalizability, and thus less overfitting [193]. Mathematical 
kernels are used to transform the data into a higher-dimensional feature space in 
order to facilitate separability by the plane. 
 
Figure 4-10 The Support Vector Machine (SVM) classification algorithm. The SVM is a 
supervised classification algorithm which is trained by finding the optimal separating 
hyperplane with the maximum distance from the nearest training objects. Here, the SVM finds 
an optimal hyperplane for separating the objects of R1 (red circles) and R2 (grey circles) with the 
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help of the support vectors (dashed lines). The hyperplane constitutes the decision boundary 
to classify an unknown pattern into one of the two regions. Taken from [193]. 
Classification of an unknown object is simple since the hyperplane serves as decision 
boundary [193]. Main disadvantage of a SVM-based classification is the extensive 
parameterization which includes kernel selection, kernel parameterization, and cost 
definition for hyperplane construction violations.  
SVMs have been successfully employed in MALDI imaging studies to classify breast 
cancer samples or prostate carcinomas [53, 103]. 
 
4.2.3 Validation of marker and classifier performance 
Particular care must be given to the validation of potential markers and classifiers 
based on signatures, as the curse of dimensionality may also result in a poor 
generalization capability (overfitting). Overfitting can occur very often in discovery-
based research where large numbers of potential features are used to discriminate a 
small number of samples [190]. As overfitting causes non-reproducible results in 
independent sample collections, the solution to test for overfitting is to assess 
reproducibility [190]. If supervised methods are employed, this may be done initially 
by cross-validation methods. The principle is to iteratively split the available samples 
into a model generation set and a test set. Each time the model is evaluated by the 
test set and the final classification accuracy is averaged across all steps. 
Reproducibility can also be confirmed when different classification algorithms were 
employed on the same problem while reaching the same results. 
However, the application of the classifier or a single marker to an independent test set 
is considered the gold-standard to evaluate reproducibility [193]. Thus, in the here 
presented studies, an independent test set was used to validate the reproducibility of 
the results — where applicable. Otherwise a cross-validation was used to assess the 
classifier’s accuracy. 
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